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Autoimmune polyendocrine syndrome type 1 (APS-1) is a rare autoimmune disease, where the 
T cells fail to distinguish between self and non-self, due to mutations in the Autoimmune 
Regulator, AIRE, gene. To ensure self-tolerance, the regulatory T cell linage (Treg) plays a 
crucial role, and AIRE is thought to be important in their development in the thymus. Patients 
with APS-1 display a wide variety of autoimmune manifestations and the treatment options are 
limited. Hence, there is a great need of studies on targeted treatment. As studies have found that 
Treg are reduced in numbers and function in APS-1 patients, we hypothesized that the 
autoimmunity in patients with APS-1 is affected by a deficiency in the development or 
differentiation of Treg modulated by the mTOR pathway. 
 
We here aim to establish a cell-based drug screening system to study the effect of the mTOR-
inhibitor rapamycin, in cell culture of PBMC from APS-1 patients and healthy controls. First, 
we investigated the expression of mTOR-related genes in blood from patients and controls to 
select genes of interest to study in our cell-based system. Then, we established an in vitro assay 
using PBMCs to study the effect of rapamycin in patients and controls.   
 
From the mTOR signaling pathway analysis, two genes (INS and mTOR) were selected in 
addition to CTLA-4, for follow-up in the in vitro assay. Overall, no large differences between 
patients and controls were found, although a trend toward decreased expression was observed 
after treatment with rapamycin. From the in vitro assay, we found that both cell proliferation 
and IFN-γ production decreased after treatment with rapamycin. At the protein level, significant 
differences of the expression of CD31, a marker for recent thymic migration, and CD39, a 
marker for Treg function, were observed. The frequency of Treg in APS-1 patients and controls 
were comparable, with a decreasing trend when treated with rapamycin.  
 
We did observe an immunosuppressive effect of rapamycin in our in vitro assay. But with a 
limited number of APS-1 patients we are unable to draw any firm conclusions from this study. 
However, we have successfully established an in vitro cell culture system to analyze the effect 
of rapamycin, which can be used for screening of other potential drugs on APS-1 patient cells 






APC: Antigen-presenting cell 
AIRE: Autoimmune regulator 
APECED: Autoimmune polyendocrinopathy-candidasis-ectodermal dystrophy  
APS-1: Autoimmune polyendocrine syndrome 1 
BCR: B cell receptor 
BSA: Bovine serum albumin 
CD: Cluster of differentiation 
CsA: Cyclosporine A 
cT: Conventional T cell 
cTEC: Cortical thymic epithelial cell 
CTL: Cytotoxic T cell 
CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4 
DC: Dendritic cell 
DMSO: Dimethyl sulfoxide 
DN: Double-negative 
DP: Double-positive 
ELISA: Enzyme-Linked Immuno-Sorbant Assay 
G-ß-L: G protein ß-subunit-like protein 
GF: Growth factor 
FKBP-12: FK binding protein-12 
FOXP3: Forkhead box P3 
Ig: Immunoglobulin  
IFN: Interferon  
IL: Interleukin 
INS: Insulin 
IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome  
iTreg: Induced regulatory T cell 
MHC: Major histocompability complex 
mTEC: Medullary thymic epithelial cell 
mTOR: Mammalian target of rapamycin 
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mTORC1: Mammalian target of rapamycin complex 1 
mTORC2: Mammalian target of rapamycin complex 2 
Nrp-1: Neuropilin-1 
NK: Natural killer  
nTreg: Natural regulatory T cell 
PPR: Pattern recognition receptor 
PAMP: Pathogen-associated molecular pattern 
PBS: Phosphate-buffered saline 
PBMC: Peripheral blood mononuclear cell 
PI3K: Phosphoinositide 3-Kinase 
PKB: Protein Kinase B 
PTEN: Phosphatase and tensin homolog 
RA: Rheumatoid arthritis 
ROAS: Register for organ specific autoimmune diseases  
S6K: Protein 6 kinase  
SLE: Systemic lupus erythematosus 
SP: Single-positive 
STAT: signal transducer and activator of transcription  
TCR: T cell receptor 
TH cell: Helper T cell 
TGF-b: Transforming growth factor b 
TLR: Toll-like receptor 
TRA: Tissue-restricted antigen 




The immune system protects the host from a wide range of viruses, bacteria and fungi that we 
are all exposed to in our daily life. When such pathogens invade an organism, it has to overcome 
several hindrances to settle in the host and cause disease. To prevent this, we are dependent on 
a rapid immune response. In vertebrates, the immune system is divided in two, the innate and 
the adaptive, each part consisting of a wide range of cells and molecules with effector functions 
(figure 1.1) [1, 2]. Cooperation between these two systems through cell-contact, cytokines and 
chemokines is crucial for their protective mechanisms [3]. This demands a strict control to 
prevent damage of tissue and providing a tolerance to “self”, where the suppressor T cell linage, 
regulatory T (Treg) cells, is considered a key controller. If this control is not maintained, an 
imbalance in immunological defence and self-tolerance can cause autoimmunity [4]. There 
exists over 80 autoimmune diseases, where some are rarer than others [5]. An example of a 
rare, monogenic autoimmune disease is autoimmune polyendocrine syndrome type 1 (APS-1). 
After onset of APS-1, the symptoms are managed by replacing hormones and suppressing the 
mechanisms driven by aberrant immunity [6]. APS-1 is a T cell mediated disease, and to 
provide a better care, the search for new treatment is needed. In the following, a brief 
introduction of the innate and adaptive immunity is given, to further focus on APS-1, the 
function of Treg in immune response, and how enhancing Treg function potentially provides a 







Figure 1.1: The cells involved in innate and the adaptive immunity. The precursors of all immune cells are 
hematopoietic stem cells from the bone marrow that differentiate into a wide range of cells with different protection 
functions. The innate immune response is mediated by granulocytes (neutrophil, eosinophil and basophil) together 
with mast cells, dendritic cells, NK cells and macrophages. The adaptive immune response is mediated by T and 
B cells, that further divide into different subclasses. The cells in the interface between the two systems are involved 
in the interaction between the systems, together with other cells, such as antigen presenting cells in the innate 
immune system. Modified from Oliveira et. al.[7] using Servier Medical Art. 
1.1  Innate immunity 
 
The innate immune system is the host’s first line of defence. This is a fast acting, natural and 
non-specific response to invaders consisting of epithelial barriers and multiple defending cells, 
that do not develop memory of the invader [8]. These cells, such as natural killer cells (NK) 
and dendritic cells (DCs) (figure 1.1), rely on recognition of pathogen-associated molecular 
patterns (PAMPs) presented on the pathogen´s surface. PAMPs are recognized by pattern 
recognition receptors (PRRs) on the surface of the immune cells, such as toll-like receptors 
(TLR) [9]. Effector mechanisms like phagocytosis can then start immediately, and chemokines 
and cytokines are produced to induce additional protective mechanisms [10]. In addition to 
cells, there are numerous circulating plasma proteins and protein fragments with an effector 
function in innate immunity. About 30 of these constitute the complement system, a highly 
efficient effector mechanism leading to a cascade of reactions. The compliment system is 
activated directly by pathogens or by antibodies released from B cells bound to the bacteria [11, 
12].  
 
Although the innate immune system is an immediate response, these immune cells do not 
recognise or manage to protect the host from all invaders and sometimes need help from the 
adaptive immune system. The crosstalk between these two systems occurs by antigen 
presenting cells (APCs), such as DCs, and signalling molecules [10, 13]. When an invader is 
recognised by PRRs on the surface of DCs, the invader is engulfed through phagocytosis and a 
peptide representing the invader is brought to the surface, bound to major histocompatibility 
complex (MHC) molecules. Further, cells of the adaptive immune system can recognise this 
peptide by binding to MHC and start an immune response [14, 15]. An example of this is when 
DCs migrate to lymphoid tissues to present antigens to T-lymphocytes that in turn initiate an 
antigen specific immune response [16].  
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1.2  Adaptive immunity 
 
The adaptive immune system is the host´s second line of defence, an acquired and specific 
response to foreign substances. Although the response is slower than for innate immunity, 
immunological memory is developed. This part consists of lymphocytes divided in  two subsets, 
T and B lymphocytes responsible for cell mediated and humoral immunity, respectively [1, 17]. 
Both T and B lymphocytes arise in the bone marrow, where the B cells also mature before 
migrating to lymphatic organs. The precursor T cells emerge to the thymus to mature before 
entering the lymphatic system [1].  
 
1.2.1 B cells 
 
B cells mature in the bone marrow where they go through clonal deletion, and self-reactive B 
cells die by apoptosis. They further migrate to the peripheral lymphoid tissue to mature into 
subsets of B cells when activated [18, 19]. This activation occurs when B cells recognize 
antigens through the B cell receptor (BCR), consisting of membrane bound immunoglobulins 
(Igs) [20]. Further, B cells differentiate into plasma- and memory-cells [21]. These subclasses 
are specialized to attack invaders, specially extracellular pathogens and toxic compounds, 
where memory cells rapidly respond when re-exposed to the specific antigen [17]. Plasma cells 
release specific antibodies, with the same antigen-specificity as their BCR, that neutralize the 
specific pathogen to further be phagocytosed by macrophages and neutrophils, also leading to 
activation of the complement system [11, 12]. To do so, B cells are dependent on activation by 
cluster of differentiation (CD)4+ T cells through recognition of antigenic peptides, presented in 
MHC class II on the B cell [22]. 
 
1.2.2 T cells 
 
T cells go through a strict process in the thymus, involving multiple proliferative selection 
events resulting in mature naïve T-lymphocytes, committed to either CD8 or CD4, also known 
as  cytotoxic T cells (CTLs) and effector T helper  (TH) cells, respectively (figure 1.1) [23]. 
These conventional T (cT) cells are involved several protective mechanisms. CTLs are involved 
in destruction of virus-infected cells and cancerous cells. They directly and specifically attack 
the infected cell by lysis, thereby preventing further replication of the pathogenic agent [24, 
25]. TH are involved in activation of both CTLs and B-cells by receptor contact and the release 
of a wide range of cytokines [16, 26]. Furthermore, TH can differentiate into the subclasses TH1, 
TH2, TH17 and Treg cells depending on the signal of initiation (figure 1.1) [27].  
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1.2.3 T cell development 
 
In the thymus, T cells go through a strict process where they differentiate into subclasses and 
are tested for functionality and autoreactivity. Precursor T cells reach the thymus through the 
blood vessels, entering the thymic stroma in a double negative (DN) state, CD4-CD8-. Further, 
these thymocytes go through multiple stages in the outer cortex where the TCR are rearranged 





Figure 1.2: T cell development in the thymus. The developing T cell goes through a positive selection in the 
cortex, before moving into the medulla going through negative selection, where a wide range of tissue restricted 
antigens (TRAs) are presented to the T cells by medullary thymic epithelial cells (mTECs). These antigens are 
induced by the autoimmune regulator (AIRE), ensuring self-tolerance. Some of the peptides are transferred to 
antigen presenting cells (APC), such as dendritic cells (DCs), also presenting them to the T cell. Modified from 
Takaba et. al.  [30] using Servier Medical Art. 
 
During positive selection, the DN thymocytes which interact with cortical thymic epithelial 
cells (cTECs) with specificity to a host MHC-peptide complex on cTECs, will be kept and exit 
the cortex as CD4+CD8+ (DP) cells, where all other cells will die by apoptosis (figure 1.2). To 
enter a single positive (SP) stage where the cells commit to either the CD4-CD8+ or CD4+CD8-
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-lineage, the cells goes through a subsequent selection, called negative selection. When entering 
the medulla, the thymocytes that bind with too high affinity against the host peptide presented 
by MHC on the surface of medullary thymic epithelial cells (mTECs) are autoreactive 
thymocytes and will go through apoptosis. Thymocytes with no or low affinity towards self-
antigens  proceed to the periphery as mature T cells (figure 1.2) [29, 31].  
 
As a part of the negative selection, the transcription factor Autoimmune Regulator (AIRE) 
control the expression of tissue-restricted antigens (TRAs), found in mTECs (figure 1.2) [32]. 
TRAs pose a self-shadow of proteins found in the hosts´ organs and cells. This process is 
essential for the development of the T cell repertoire and the acquisition of self-tolerance [31, 
33, 34]. It is further suggested that AIRE also has a pivotal role in thymic selection of regulatory 
T cells (Treg) which control the activity of TH cells in the peripheral tolerance [33, 35, 36]. The 
development of Treg is suggested to occur when the immature thymocytes recognize TRAs with 
an intermediate strength, where the expression of Forkhead boxP3 (FoxP3) commits the T cell 
to a Treg fate [37].  
 
1.2.4 T cell activation 
 
Both naïve and memory T cells continuously patrol secondary lymphoid organs [23], searching 
for pathogens presented by an APC. By cell mediated immunity, the TCR complex consisting 
of CD3 together with the co-receptor  CD4 or CD8, can interact with MHC glycoproteins; CD4 
interacts with MHC class II, and CD8 with MHC class I (figure 1.3) [16]. Peptides fits in 
specialised binding sites of MHC glycoproteins, and a specific immune response is initiated 
towards the protein that the peptide is derived from [38, 39]. In addition to these interactions, 
other co-stimulatory signals are needed for activation of the immune response. Such signals are 
induced by CD28, a protein presented on the T cell to interact with CD80/CD86 presented on 
APCs (figure 1.3). This occurs when the affinity between the TCR and MHC is strong enough, 
if not, CD28 will not be presented on the T cell and it goes into anergy, a state where T-cells 
fail to respond and are unable to be re-stimulated [40-42]. 
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Figure 1.3: Activation of T cells by an antigen presenting cell (APC). The activation of T cells goes through 
several signals. A peptide bound MHC on the surface of the APC is presented to the T cell and binds to CD3 and 
CD4 or CD8, dependent on the T cell, in addition to co-stimulatory signals through CD86/80 and secretion of 
cytokines. Modified from [43]  using Servier Medical Art. 
 
Finally, to complete the activation, a signal involving inflammatory cytokines such as 
interleukin (IL)-12, IL-2 and type I interferons (IFN) is needed [44]. CD28 also provides naïve 
T cells with a co-stimulatory signal for promoting IL-2 production and cell expansion, 
preventing anergy induction and cell death. In contrast, the cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4), competes with CD28 for the binding of CD80/CD86, and “down-regulate” 
the effector mechanisms when bound [36]. The expression of CTLA-4 is strictly regulated and 
is localized both intracellular and extracellular. Further, it is suggested that the extracellular 
CTLA-4 receptor is upregulated upon activation of T cells [45]. The CTLA-4 receptor provides 
a suppressive function and is associated with Treg, where it is constitutively expressed [43, 46].  
 
1.2.5  Regulatory T cells 
 
Treg are also known as suppressor T cells and are a subpopulation of TH cells, playing a role in 
maintaining peripheral tolerance to self-antigens, and constitutes between 5-10% of the 
peripheral CD4+ T cell pool [47]. Attention is given to this specific subpopulation for their 
ability to control inflammation and autoimmune responses, to promote the growth of tumour 
cells [48], and especially for its ability to suppress proliferation of self-reactive CD4+ and CD8+ 
T cells [49]. CD4+CD25+ Treg can be divided in two subpopulations, naturally arising Treg (nTreg) 
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and induced Treg (iTreg). nTreg differentiate in the thymus before migrating to the periphery, 
whereas iTreg diverges from TH cells in the periphery [50].   
 
To discriminate Treg from other CD4+ T cells in experimental studies, both extracellular and 
intracellular markers are used. FoxP3 as an intracellular marker was defined as the master 
transcriptional factor linked to the function of Treg along with the α-chain of the extracellular 
IL-2 receptor (IL-2R), CD25 [48, 51]. Even though many T cells express CD25 upon activation, 
studies have shown that mice with IL-2 deficiency developed severe multi-organ autoimmunity 
due to a poor pool of CD4+CD25+ T cells [36]. Similar effects have also been shown for CD25 
deficient mice, but these could be prevented by injecting them with CD4+CD25+ T cells from 
normal otherwise genetically identical mice [36, 52]. These two studies indicate that IL-2 and 
CD25 is crucial in preventing autoimmunity, and further suggested that IL-2 signaling is linked 
to the expression of FoxP3 in both nTreg and iTreg  through the signalling pathways PI3K, Akt 
and mTOR [52]. IL-2 leads to inhibition of these signalling pathways and increases the 
expression of FoxP3 [53, 54], resulting in a larger pool of Treg. Furthermore, studies in mice 
implicate that T cells with mTOR-deficiency differentiate into FoxP3+ T cells [55].  
 
To distinguish between nTreg and iTreg it has been suggested that the markers Helios, Neuropilin-
1 (CD304) and CD31 can be used. Helios, a member of the Ikaros transcription factor family 
and an intracellular marker, is suggested to be restricted to nTreg, and to have a role in 
maintaining stability and regulatory function of Treg [48]. The extracellular marker CD304 is 
identified to be expressed in nTreg [56], stabilizing the expression of FoxP3 by potentiating 
PTEN, a protein phosphatase negatively regulating PI3K [48]. CD31 is an extracellular marker 
with high expression in T cells recently emigrated from the thymus, while T cells with lower 
expression of CD31 are suggested to be aged TH  cells reflecting a reduced thymic output [57].  
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Figure 1.4: Regulatory T cell suppressive function.  Regulatory T cells have multiple suppressive functions, by 
producing the immune suppressive cytokines IL-10 and TGF-ß, and with the expression of IL-2R to bind up IL-2, 
making the cytokine less available for non-regulatory T cells. Furthermore, the expression of inhibitory molecules, 
CTLA-4 and CD39, inhibit maturation of DCs and activation of effector T cells, respectively. Bars represent 
inhibition. Modified from Braza et.al. [58] using Servier Medical Art. 
 
There are probably several modes of function for Treg (figure 1.4). It is suggested that the high 
expression of CD25 on Treg competes for the IL-2 produced by TH cells , making it less available 
for nonregulatory T cells [59]. Furthermore, it has been shown that the immunosuppressive 
function of Treg is dependent on CTLA-4. This surface receptor is important as a checkpoint 
inhibitor for autoreactive T cells as a homolog to CD28 with higher binding strength, which 
does not stimulate the production of cytokines.  [43, 46]. Another receptor expressed on Treg 
cells having immunosuppressive properties is the ectoenzyme CD39, which alternate the level 
of adenosine in the environment surrounding Treg (figure 1.4) [60, 61].  
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In addition to interacting directly through cell-to-cell contact, Treg produces the cytokines IL-
10 and TGF-ß, which are central for their suppressive function (figure 1.4). IL-10 inhibits the 
production of other cytokines important for immune responses in T cells and have an anti-
inflammatory and suppressive effect on most haematopoietic cells. TGF-ß has an 
immunomodulatory effect by suppressing the function in multiple cells [46, 62, 63], in addition 
to play a role in maintaining the peripheral Treg population and suppressing IFN-γ, a 
proinflammatory cytokine produced by activated T cells [54, 64]. Furthermore, it has been 
shown in mice that TGF-ß inhibits the antigen-specific proliferation of naïve T cells [65].  
 
With all mechanisms mentioned above, Treg have a crucial role in maintaining peripheral 
tolerance, preventing autoimmunity. When this tolerance is broken either due to the lack of Treg 
or dysfunction in this subpopulation it can cause severe autoimmunity [36, 37].  
 
1.3  Autoimmunity 
 
Up until the 1950s, the idea of the immune apparatus attacking self-antigens was questioned 
and considered absurd [66]. Now it is well established that autoimmunity occurs, even though 
the details of the pathogenesis and etiology of most autoimmune diseases is not fully understood 
[67]. When trying to understand the origin, researchers have suggested that autoimmunity can 
be influenced by genetics, gender, environment and medicines, and that viral infections can 
break down the tolerance to self and trigger an autoreactive cascade [68-70]. Autoimmune 
diseases affect approximately 8% of the general population, where women are most affected. 
What is clear is that autoimmunity is a result of an imbalance between effector and regulatory 
immune responses [71].  
 
Based on the immune response, autoimmune disorders can be divided into two classes, organ-
specific and systemic autoimmune diseases [72, 73]. An example of systemic autoimmunity is 
systemic lupus erythematosus (SLE), where almost any organ in the body could be a target for 
autoimmune inflammation. In SLE the targets for the immune response are typically ubiquitous 
expressed substances like DNA [74]. In contrast, tissue-restricted autoimmune disease is 
directed against self-antigens presented in one (or several) particular organ or tissue, such as 
type 1 diabetes or autoimmune primary adrenal insufficiency (Addison´s disease). When a 
person acquires more than one organ specific endocrine autoimmune disease, it is called an 
autoimmune polyendocrine syndrome [75]. 
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1.4  Autoimmune polyendocrine syndrome type 1 
 
Autoimmune polyendocrine syndrome type 1 
(APS-1) is a rare condition also referred to as 
autoimmune polyendocrinopathy- candidiasis-
ectodermal dystrophy (APECED) [76]. It has a 
prevalence of roughly 1:100.000 in most countries 
and is estimated to occur in about 1:90.000 in 
Norway [76, 77]. This polyglandular disorder is 
diagnosed when at least two of the three following 
manifestations is present; chronic mucosal 
candidiasis, chronic hypoparathyroidism and 
Addison´s disease, where the first signs of APS-1 
usually occur early in childhood [78]. In addition 
to these manifestations, a number of other 
endocrine and non-endocrine symptoms also occur 
frequently such as enamel hypoplasia, enteropathy, 
pancreatic insufficiency pneumonitis, and primary 
ovarian failure (figure 1.5) [6, 76]. These patients 
have a high death and mortality rate, where most of 
the deaths occur before the age of 45 years, and the 
most common causes of death are due to the 
endocrinopathies, such as hypocalcemia and 
adrenal crisis [79].  
The disease is characterized by autoantibodies against several defined antigens, such as 
autoantibodies against the enzyme 21-hydroxylase (21-OH), expressed in the adrenal cortex 
[75]. Some autoantibodies appear early in the development of the disease, such as those against 
the immune mediators IFN-alpha (α) and especially IFN-omega (ω). These autoantibodies are 
apparently restricted to APS-1, making it possible to diagnose APS-1 early [80]. 
APS-1 is an autosomal recessive T cell mediated disease caused by loss of function of the AIRE 
protein. Mutations in the AIRE gene causes potentially autoreactive T cells to escape negative 
selection, further leading to autoimmune inflammation in selected organs [77]. This is thought 
to be a plausible explanation for why APS-1 patients have autoimmunity to multiple organs 
Figure 1.5: Clinical manifestations of APS-1 
There are many potential manifestations and 
great variation among patients. Figure from 
Husebye et. al [6]. 
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[32]. In addition, the differentiation of Treg seems to be affected [33]. A flow cytometry study 
of PBMC showed that the frequency of CD4+ CD25+ FoxP3+ Treg in APS-1 patients was 
significantly lower than in age- and sex-matched healthy controls [81]. The deficiency of Treg 
in APS-1 patients could be due to the lack of both thymic development and peripheral activation 
[82]. In the periphery this could be due to lack of necessary activation signals, that T cells fail 
to upregulate FoxP3 upon activation [83], or that conventional T cells are resistant to the 
suppressive mechanisms of Treg [84].  
 
1.5  Pharmacological treatment of APS-1 
 
Today the treatment of patients with APS-1 is based on their manifestations, where chronic 
mucocutaneous candidiasis generally is managed with oral nystatin (azole drug) and oral 
amphotericin B (polyene drug). Hypoparathyroidism is treated with oral vitamin D in 
combination with calcium and magnesium supplements, or parathyroid hormone [6]. Addison’s 
disease is treated with cortisone acetate and fludrocortisone [76]. In the treatment of APS-1 
patients there are several challenges, both due to the disease and the medication. Some patients 
have malabsorption leading to poor absorption of calcium and vitamin D [85]. On top of that, 
there are challenges with interactions between the drugs in the treatment, and that drugs are 
vulnerable to resistance. The azole drugs mechanism works by targeting ergosterol, the major 
sterol in the fungal plasma membrane [86]. By inhibiting the steroidogenesis, there is a risk of 
inducing adrenal insufficiency [6]. To avoid azole-resistance, azole drugs are combined with 
the polyene amphotericin B, an antifungal agent with another mechanism [76, 86].  
 
Some patients are also treated with immunosuppressant cyclosporine A (CsA) to improve 
pancreatic insufficiency [85]. The mechanism of action of CsA is by blocking the transcription 
of cytokine genes such as IL-2 and IL-4, hence, inhibiting T cell activation [87]. Rituximab, 
another immunosuppressant has been reported to prevent pneumonitis and malabsorption [76]. 
Rituximab binds to CD20 on B-cells and induces cell death and B cell depletion [88]. To get a 
better treatment for patients with APS-1 the best target is yet to be identified, and there is a 
need for studies of drugs with possible beneficial immunosuppressant functions. A potential 
target for treating APS-1 could be expansion of Treg, which seems to be central in the 
dysfunctional immune system in APS-1 patients.  
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1.6  The role of mTOR in autoimmunity and expansion of Treg 
 
The protein kinase mammalian target of rapamycin (mTOR) is a member of the phos- 
phatidylinositol-3-OH kinase (PI3K)-related kinase family, a complex intracellular signaling 
pathway. mTOR consists of two multi-protein complexes, mTOR complex I (mTORC1) and 
mTOR complex II (mTORC2), put together with the regulatory associated proteins Raptor and 
Rictor, respectively, in addition to G protein ß-subunit-like protein (G-ß-L) (figure 1.6) [89, 
90]. The role of mTOR is broad, having an impact in several mechanisms regulating cell growth 
and several cellular processes.  
 
Figure 1.6: Signaling network of mTOR. The role of mammalian target of rapamycin (mTOR) is broad, having 
a central role in cell growth and proliferation. The signaling network is complex, where activation and inhibition 
can be stimulated by several factors. Arrows and bars represent activation and inhibition, respectively. Figure 
modified from Tsang et. al. [91]. 
 
mTOR is shown to be crucial for the function and development of Treg and TH cells. An 
increased signaling through mTOR can magnify the inflammatory environment in TH cells. In 
Treg, by contrast, the activity of mTOR has to be held back to maintain their suppressive function 
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[48]. Activation of mTOR goes through several mechanisms, where the enzyme 
phosphatidylinositol 3-kinase (PI3K) and Akt has central roles, in addition to loss of the tumor 
suppressor phosphatase and tensin homolog (PTEN) (figure 1.6) [90, 92].  
 
IL-2 signaling through IL-2R and prolonged occupation of the TCR and CD28 surface molecule 
[93], or stimulation with growth factors (GF), can lead to activation of PI3K and a 
phosphorylation cascade activating Akt [90, 94]. mTORC1 is the major downstream 
component, regulating cell proliferation and metabolism (figure 1.6) [95]. Inhibition of 
mTORC1 is shown to increase the amount of Treg in addition to suppress T cell activation and 
proliferation, hence giving a immunosuppressive effect promoting immune tolerance [96]. 
Moreover, CD4+ T cells with a lack of mTOR were unable to differentiate into effector cells 
[89]. 
 
Drugs inhibiting the mTOR-signaling pathway are used in the treatment of cancer, allograft 
rejection and some autoimmune disorders. Such drugs are everolimus, temsirolimus and 
rapamycin [97].  
 
1.7  Rapamycin, a mTOR inhibitor 
 
Rapamycin, also known as Sirolimus, was first isolated in the early 1970s from a solid sample 
of Streptomyces hygroscopic discovered on the Easter Island, where this macrolide was found 
to be a potent anti-fungal agent (Figure1.7) [98]. Studies also showed that this inhibitor of 
mTOR has a strong immunosuppressive effect, as mTOR is an important regulator of T cells 










Figure1.7: Molecular structure 
of rapamycin. The mTOR-binding 
domain is coloured in pink and the 
FKBP-12 binding domain is 
coloured in blue. Figure from 
Tsang et. al. [91]. 
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Rapamycin interacts with the immunophilin FK binding protein-12 (FKBP-12) to be biological 
active, making a complex inhibiting mTORC1 in a direct and potent way (figure 1.8) [91, 100, 
101]. This leads to suppression of cT cells by blocking the cytokine-stimulated protein synthesis 
[95, 102], and inhibition of the T cell-cycle progression by blocking G1 to S phase after 
activation [103]. This also affects the differentiation of TH cells, where mTORC1 activation is 
necessary for the differentiation of TH1 and TH17 cells, and mTORC2 in the case of  TH2 cells 
[55, 89, 104]. In addition, rapamycin has been shown to stimulate the catabolic processes 
autophagy and cell death [91, 101, 105]. Further it is suggested that rapamycin promotes TCR-
induced T cell anergy in the presence of co-stimulation, and blocks IL-2-induced proliferation 








Figure 1.8: The effect of 
rapamycin on T cells. Rapamycin 
binds to FKBP-12 making a 
complex inhibiting mTORC1 and 
blocks the cell cycle in G1 to S 
phase, thereby inhibiting the 
differentiation of TH1 and TH17, and 
cell growth. Naturally mTOR 
downregulates the expression of 
FoxP3 and stops autophagy, in the 
presence of rapamycin these 
functions are blocked. Arrows and 
bars represent activation and 
inhibition, respectively. Modified 
from Mcmahan et. al. [96] and 
Chapman et. al [56]. 
  
 23 
In contrast to cT cells, it is suggested that Treg are less sensitive to rapamycin due to their high 
expression of PTEN, where IL-2 stimulation leads to JAK/STAT signaling regulating FoxP3 
[96]. Others suggest that rapamycin promotes the function of Treg due to stabilization of FoxP3 
expression [48]. A study in cell culture has shown that Treg treated with a pulse treatment of 
rapamycin had an increased expression of CD25 and CTLA-4, giving them an enhanced 
suppressive function compared to nontreated Treg [106]. 
 
Not only has rapamycin an effect on T cells, it is suggested that rapamycin also has a 
suppressive effect on antigen-presenting cells, such as IL-4 dependent DC maturation, reducing 
DC-mediated antigen uptake and presentation, and consequently less activation of T cells [104]. 
 
1.8  Clinical use of rapamycin 
 
The pharmaceutic rapamycin, mainly used to prevent transplant rejection, is thought to be a 
beneficial therapeutic in autoimmune diseases. Clinical studies have shown the effect of 
rapamycin in RA, a T cell mediated autoimmune disease, where the dysfunction of T cells is 
associated with activation of mTOR and a lack of peripheral Treg  [107]. Another example is SLE, 
where an open-label clinical trial suggests that the disease activity was reduced due to treatment 
with Rapamycin [108]. Interestingly, rapamycin has been shown to successfully control 
gastrointestinal and dermatologic symptoms and reduced the inflammatory reactions, in the 
monogenic autoimmune disease immunodysregulation polyendocrinopathy enteropathy X-
linked syndrome (IPEX), a disease where the clinical picture has some overlap with APS-1. 
IPEX is a rare disease also being T-cell mediated, with a dysfunction in the transcription factor 
FoxP3 [6, 109, 110]. With the effects suggested in IPEX, RA and SLE, rapamycin could potentially 
have a positive effect on APS-1 patients, being a monogenic T cell mediated disease that can be 
associated to the mTOR-signaling pathway.  
 
Even though rapamycin has several beneficial effects as an immunosuppressant, there are some 
side effects that have to be taken into consideration in treatment. The optimal dose varies in 
patients, and also does the likelihood of potential side effects, where weekly drug monitoring 
is required to titrate the dose [111]. Rapamycin is available in tablet form and oral solution. The 
oral absorption is poor, with an extensive uptake in erythrocytes [112]. In a clinical report, 
IPEX patients were treated with 0.15 mg/m2 rapamycin daily with oral administration, and the 
serum levels were in the range 8-15 ng/mL [109]. Suppressing the immune system is likely to 
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predispose the host to viruses, infections, and even cancer. Studies have shown that some 
patients treated with rapamycin had higher cholesterol levels, and leuko-and thrombocytopenia 
were observed in others [113, 114]. In a long term treatment for five years of three IPEX 
patients using rapamycin, no significant side effects was reported [109, 110]. But as rapamycin 
is largely metabolized in the intestine and liver by cytochrome P450 (CYP) 3A4, an enzyme 
involved in the metabolization of several drugs, there is a risk of interaction with other 
treatments [112]. 
 
1.9  Research front 
 
In the search for new targets to treat APS-1, mTOR was chosen for this project, due to a 
preliminary study performed by a previous master student, Marte Heimli. In the study, a 
significant increase in the expression of mTOR in patients with APS-1 compared with healthy 
controls was discovered. mTOR has an important role in the development of the Treg linage, 
which has been shown to be reduced in APS-1 patients in comparison with age-and sex-
matched healthy controls [81].   
 
Furthermore, the research group is aware that clinical specialists in APS-1 have used the 
mTOR-inhibitor rapamycin in off label treatment of malabsorption in severe cases (personal 
communication). Rapamycin is also used in other diseases where there is a lack of Treg, such as 
RA and SLE [107, 108]. In several IPEX and IPEX-like patients it was shown that rapamycin 
successfully controlled the gastrointestinal and dermatologic symptoms and reduced the 
inflammatory reactions for up to five years without significant side effects [109, 110].  
 
By repurposing drugs, already validated and approved medication is investigated for the 
potential benefit in other disorders than its original intended use. This strategy to identify new 
treatment is both time- and cost-saving, and most importantly safer to use as the 





1.10 Hypothesis and aim 
 
Our hypothesis is that the autoimmunity in patients with APS-1 is affected by a deficiency in 
the development or differentiation of Treg modulated by the mTOR pathway. To explore this, 
we aimed to establish a cell-based drug screening system and specifically study the effect of 
treating PBMC from APS-1 patients with the mTOR-inhibitor, rapamycin.   
 
 
The specific aims are:  
1) Establish a cell-based system to test the outcome of different drugs at the KG Jebsen 
Centre for Autoimmune Diseases 
 
2) Assess the gene expression pattern in the mTOR-signaling pathway at the RNA level 
in APS-1 patients and controls 
a. Assessment of the gene expression in whole blood from controls and patients, 
in order to select candidate genes to be further assessed in samples treated with 
rapamycin by qPCR.  
b. Determine the expression of the candidate genes (from 2 a) in activated PBMC 
treated or untreated with rapamycin in cell culture, from controls and patients 
by the use of qPCR.  
 
3) Investigate the outcome of rapamycin treatment of PBMC at protein level 
a. Determine the expression of selected markers for Treg in activated PBMC 
treated or untreated with rapamycin in cell culture, for controls and patients by 
the use of flow cytometry.  
b.  Determine the levels of IFN-γ in activated PBMC treated with rapamycin in 
cell culture by ELISA, to assess the differences in samples treated with 





2.1 Chemicals and reagents  
 
Reagents and chemicals Supplier Ref.No. 
Dulbecco’s Phosphate 
Buffered Saline 
Sigma Life Science D8537 
AB serum Sigma Life Science H4522 
Dimethyl Sulphoxide (DMSO)  Sigma-Aldrich D2650 
FBS, Quaified, HI Gibco 10500-064 
PAXgene blood RNA-kit  Qiagen 762174 
RNeasy micro plus kit Qiagen 74034 
RLT buffer Qiagen 79216 
BD Pharm Lyse BD Biosciences 555899 
b-mercaptoethanol Aldrich chemistry  M6250  
Absolutt Alkohol Kemetyl Norge  200-578-6  
RNeasy micro plus kit  Qiagen 74034 
RT2 Profiler PCR Array, 
Human mTOR Signaling 
Qiagen KD02-R1 
Anti-CD3 V500, clone UCHT1 BD 561416 
Anti-CD25 PE-Cy7 BD 335824 
CellReace CFSE cell 
proliferation kit 
Thermo Scientific C34554 
RPMI-1640 Medium Sigma-Aldrich R7388 
L-glutamine Sigma-Aldrich G5792 
Penicillin-streptomycin Sigma-Aldrich P4333 
Rapamycin  Sigma-Aldrich R0395 
Live/dead Fixable Yellow 
Dead Cell stain kit  
Life technologies L34959  
BSA   
Human Fc block BD 564220 
Anti-CD4 FITC, clone M-T466 Miltenyi Biotec 130-080-501 
Anti-CD4 AF700, clone RPA-
T4 
BD 557922 
Anti-CD8 PerCP-Cy5.5, clone 
SKI 
BD 65310 
Anti-CD25 PE, clone 4E3 Miltenyi Biotec 130-091-024 
Anti-CD45RA APC-H7, clone 
HI100 
BD 560674 
Anti-CTLA4 BV421, clone 
BN13 
Biolegend 369606 
Anti-CD39 PE, clone ebioA1 Invitrogen 12-0399-42 




BV650, clone U21-1283 
BD 8297659 




Anti-CD127 APC, clone 
MB15-18C9 
Miltenyi Biotec 130-098-121 
Anti-Helios APC, clone 22F6 Biolegend B260687 
TaqMan Gene Expression 
Master Mix 
Applied Biosystems 4369514 





CTLA-4, TaqMan gene 




mTOR, TaqMan gene 









RNA 6000 Pico Reagents Agilent Technologies  5067-1513  
High capacity RNA-to-cDNA 
kit 
Applied Bisosystems 4387406 
SuperScript III first-stand 




DEPC Treated Water Invitrogen AM9915G 
Water Nuclease Free VWR 436912C 
MACS BSA Stock Solution Miltenyi Biotec 130-091-376 
Phosphate buffered saline 
99.5%  
Sigma Life Science  D8537  
Superscript III first-strand 
synthesis system for rt-PCR 
ThermoFisher 18080051 
ELISA MAX Deluxe set for 
Human IFN- γ  
BioLegend 430104 
 
Tween 20 Sigma-Aldrich 9005-94-5 
Sulfuric acid, (H2SO4) Sigma-Aldrich 339741 
 
 
2.2  Equipment 
 
Equipment and consumables Supplier Ref.no. 
CPT-tubes BD 362753 
PAXgene blood RNA tubes BD 762165 
Vortexer V1S000 IKA 4047700 
5810R Centrifuge Eppendorf  
Heraeus multifuge 3SR+  Thermo Fischer   
Kinetic energy 26 joules 
minicentrifuge  
VWR C1413V  
Thermomixer Eppendorf  
Disposable pipettes  VWR  1612-1613  












Clip-tips 300 μL Thermo Scientific 94420513 
Finnpipette F1 pipettes Thermo Fischer   
Fastpette Pipetboy Integra  
Pipette tips, 10 mL  Sterilin  475110  
Centrifuge tubes 15 mL VWR 21008-216 
Centrifuge tubes 50 mL VWR 21008-242 
Polypropylene round-bottom 
tube, 5 mL 
Falcon 352063 
Safe-lock tubes 1.5 mL Eppendorf 0030 120.086 
Cryogenic vials 1.5 mL Nalgene 5000-1020 
MicroAmp 8-tube strip, 0.2 μL  Applied Biosystems  N8010580  
MicroAmp 8-cap strip  Applied Biosystems  N8010535  
MACSxpress separator MiltenyiBiotec 130-098-308 
LS Column MiltenyiBiotec 130-042-401 
MidiMACS separator  MiltenyiBiotec 130-042-302 
Scepter sensor 40 um EMD Millipore 
corporation 
PHCC40050 
MicroAmp Optical 96 well 
reaction 
ThermoFisher N8010560 
384 Well Multiply PCR Plate Sarstedt 72.1984.202 
Load Cover Qiagen KH29 
MicroAmp Optical Adhesive 
film 
Applied Biosystems 4213663 
QiaShredder Columns Qiagen 79656 
MicroAmp 8-tupe strip, 0.2 μL Applied Biosystems N8010580 
MicroAmp 8-cap strip Applied Biosystems N8010535 
Flowmi Cell Stainer 40 uM Bel-Art H-B Instruments J333189 
Chip Priming station Agilent Technologies  5065-4401  
RNA Pico Chips Agilent Technologies  5067-1530  





2.3  Instruments 
 
Instruments Supplier  
Scepter 2.0 cell counter Merck 
LSR Fortessa flow cytometer BD 
NanoDrop ND-1000 Spectrophotometer Saveen Werner 
ABI Prism 7900HT sequence detection system  Thermo Fisher  
Agilent 2100 Bioanalyzer Agilent technologies 
Spectramax Plus Molecular Divices 




2.4  Software 
 
Program Supplier 
ABI Prism 7900 HT SDS 2.3 Applied Biosystems 
FlowJo 10 FlowJo, LLC 
ND-1000 3.8 Thermo Fisher 
2100 Expert Agilent Technologies 
GraphPad prism 8.0 GraphPhad Software 
SoftMax Pro Molecular Divices 









Figure 3.1: Overview of the experimental pipeline. For the rt-qPCR of resting cells (left panel) RNA was 
isolated from whole blood collected in PAXgene tubes. For the experiments with activated cells (right panel) 
peripheral mononuclear cells (PBMC) were isolated from whole blood by density gradient centrifugation. RNA 
from PBMC and PBMC treated with rapamycin in cell culture were used for real-time qPCR. Flow cytometry of 
PBMC treated with rapamycin in cell culture was performed to assess the levels and phenotypes of Treg in patients 
and controls. The supernatant from PBMC treated with rapamycin in cell culture were collected for assessment 
of IFN- γ production. 
 
The main experimental methods used in this project are cell culture, flow cytometry, real time 
quantitative polymerase chain reaction (rt-qPCR) and ELISA. The source to the material used 
to implement these methods is whole blood and peripheral mononuclear cells (PBMC) isolated 
from patients with APS-1 and healthy blood donors. The experimental pipeline is illustrated in 





3.2  Methodological considerations 
 
Two of the main techniques used in this project are cell culture and flow cytometry. PBMC 
isolated from APS-1 patients and healthy controls were activated and treated with rapamycin 
to further grow in cell culture. Flow cytometry was chosen to assess the populations of activated 
cells and Treg at protein level, where treated cells from cell culture were stained using 
fluorochrome-conjugated antibodies specific for the molecular target of interest. This laser-
based technology analyzes single cells or particles by measuring fluorescence from the 
antibodies bound to the cell. When the cell passes the laser, the fluorochromes are excited to a 
higher level and spontaneously emits light (fluorescence) at a longer wavelength. The emitted 
light in the form of fluorescence is collected at selected wavelengths. This makes it possible to 
measure cell populations expressing specific proteins when antibodies against the proteins are 
labeled with different fluorophores [115]. In order to assess the proliferation of the cells 
carboxyfluorescein succinimidyl ester (CFSE) staining were used which measures the amount 
of cell divisions in the culture [116]. Calculations were performed by FlowJo software 10.6.2. 
 
To investigate the change in expression of markers in controls and patients treated with 
rapamycin, the  Frequency of cells (formula 1) was calculated and differendes between 
patients and controls further determined statistically by a non-parametric Mann-Whitney test. 
 
(Formula 1) Frequency of cells (untreated) – Frequency of cells (treated with rapamycin)  
=  Frequency of cells 
 
Rt-qPCR is a method used to assess the expression level of selected genes at the mRNA level. 
The rt-qPCR methods were performed in four steps; extraction of mRNA from material, 
synthesise cDNA for mRNA by reverse transcription, amplification of a specific DNA 
sequence, and detection of the amplified product. The SYBR green technique was used to assess 
the gene expression in resting untreated cells, to choose the genes of interest for further analysis 
downstream in activation- and rapamycin treatment experiments. In the method, the SYBR 
Green dye fluoresces when attached to the double-stranded DNA, generated during the PCR 
reaction [117].  
 
To assess the gene expression in cells treated with rapamycin the TaqMan technology was 
chosen, as it is considered a highly sensitive method, and even more specific than SYBR Green. 
 32 
Here, a TaqMan probe binds to the single-stranded DNA, where a fluorescent reporter and a 
quencher are attached to the 5´and 3´ends of a TaqMan probe. During polymerization, the DNA 
polymerase cleaves the reporter dye from the probe, leading to emission of fluorescence. 
Common for both methods is that the more double-strand product produced, the more 
fluorescence is detected, and for each cycle the number of templates for each gene investigated 
is duplicated, and the earlier the signal reaches a threshold the more gene is expressed. For each 
method the output is given in the form of a Ct-value, a fractional PCR cycle number which is 
determined when the reporter fluorescence exceeds a given minimal threshold [118, 119].  
 
The raw Ct-values were used to calculate the relative quantification, using the Ct method. 
The target of interest was normalized to a housekeeping gene (HK) (formula 2). Further, the 
difference in Ct between the sample and calibrator was calculated giving Ct ( formula 3). 
Finally, Ct is used to calculate the fold-change, a relative expression value of the gene of 
interest (formula 4) [120].  
 
(Formula 2) Ct (target) - Ct (HK)= Ct 
 
(Formula 3)  Ct (sample) - Ct (calibrator) =Ct  
 
(Formula 4) 2-Ct = Fold-change 
 
As an approach to normalize the Ct for the samples treated with rapamycin, the untreated 
samples were used as calibrator.  
Enzyme-Linked Immuno-Sorbant Assay (ELISA) is a sensitive technology used to measure the 
amount of proteins in a sample. In this project it was used to detect the amount of IFN- γ in the 
supernatant from the cell culture, produced by cells in cell culture treated with rapamycin (+) 
compared with untreated (-) cells. The selected approach was a commercial sandwich ELISA, 
where capture antibodies attached to the bottom of a well captures the protein of interest, while 





3.3  Patients and controls 
 
The APS-1 patient samples were supplied from the world´s largest registry and biobanks of 
samples from patients with organ specific autoimmune diseases (ROAS), collected by the 
Endocrine Medicine research group at the Department of Clinical Science, University of 
Bergen/Haukeland University hospital. The biobank includes samples from patients with 
Addison´s diseases, where about 50% have an autoimmune polyendocrine syndrome (APS) and 
about 6% (N=48) are APS I-patients with mutations in AIRE. This unique biobank contains 
PBMCs, EDTA blood and sera. 
 
The control samples were obtained from healthy blood donors from the local blood bank at 
Haukeland university hospital (HUS). In this project 12 patients (4 females, 8 males, 30-72 
years old) and 14 controls were used, matched in both sex and age (± 8 years). Detailed 
information about patients and controls are listed in appendix (table A.1 and A.2).  Patient and 
control samples 1-5 and control 14 was included in the study with treatment of PBMC with 
rapamycin, while the patient samples 1 and 6-12, and control samples 6-13 was included in the 
study identifying gene expression in the mTOR signalling pathway.  
 
3.4  Ethical aspects 
 
All patients and controls included in this project have given written consent to use their samples 
in research. This project goes under the research projects “Immunological and genetic causes 
of organ specific autoimmune diseases” (project number: 2018/1417), “Autoimmune 
polyendocrine syndrome type 1” (project number: 2009/2055), and is approved by the Regional 
Ethical Committee of Western Norway.  Biobank project number: 2013/1504. 
 
3.5  PBMC isolation using vacutainer cellular preparation tubes 
(CPT) 
 
Fresh blood (6-8 mL) was collected in CPT-tubes, containing heparin and Ficoll, and 
centrifuged at 1800 x g for 15 minutes at 20°C. The layer of mononuclear cells was collected 
to a separate tube filled up with PBS to a total volume of 15 mL to be centrifuged at 300 x g 
for 15 minutes at 20°C. The supernatant was removed, the pellet diluted in 10 mL PBS and 
counted using a scepter handheld cell counter from Merck. Further, the cells were centrifuged 
at 300 x g for 10 minutes, the supernatant was removed, and the cells resuspended in 500 μL 
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with AB serum 10% (v/v) DMSO. The samples were frozen gradually to -80°C for 24-72 hours, 
and subsequently stored at -150°C until use.  
 
3.6  Cell culture and validation of rapamycin concentration 
 
To determine a suitable concentration of rapamycin, serial dilutions was prepared in 
preliminary cell culture experiments with the concentrations 0.05 nM, 0.1 nM, 1 nM, 2 nM and 
4 nM. Each concentration was prepared with DMSO/medium as described below. The 
concentration of 4 nM rapamycin was decided to be used for the rest of the project. 
 
Wells were coated with anti-CD3 (1 μL/mL) and incubated for 2 hours at 37 °C, or overnight 
at 4 °C. PBMC were quickly thawed before diluted in 10 mL medium (37 °C) and centrifuged 
at 300 x g for 10 minutes. MACS dead cell removal kit was used to remove dead cells, following 
the producer’s protocol and live cells were counted using the Scepter handheld cell counter 
from Merc. The cells were washed with 10 mL RPMI medium (10% FBS, 1% L-glutamine, 1% 
penicillin-streptomycin) at 300 x g for 10 minutes, the supernatant removed, and the cells 
resuspended in 1 mL PBS (37°C). The cells were stained with CFSE (5 mM) and incubated for 
10 minutes at 37°C. To finish the staining, 2 mL FBS (4°C) were added and the cells incubated 
on ice for 5 minutes. After incubation, medium (37°C) were added to a total volume of 15 mL 
and the samples were centrifuged at 300 x g for 10 minutes, the supernatant removed, the pellet 
resuspended in medium (2 million cells/mL) and anti-CD28 (5 μL/mL) was added. Further, 100 
μL cell suspension was added to each well in triplets or more, depending on the number of cells. 
Rapamycin were dissolved in 1 mL DMSO to a concentration on 25 nM, to further be diluted 
in medium to the chosen concentration. Rapamycin was diluted in 100 μL medium before added 
to the cells, while untreated cells received 100 μL medium. The cells were incubated for three 
days at 37°C with 5% CO2 before being split in to two wells and further incubated for two days 
and collected at day five. 
 
3.7  RNA isolation from PBMC 
 
RNA from PBMC treated with rapamycin in cell culture from patient and control 1-5 (section 
3.6), was purified using RNeasy micro plus kit from Qiagen, following the manufacture´s 
protocol. Briefly, the sample was collected and resuspended in 350 μL RLT lysis buffer and 
added to a Qiashredder spin column and centrifuged at max speed for two minutes. The lysate 
was transferred to a gDNA eliminator spin column and centrifuged for 30 seconds at 104 rpm. 
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The flow through was collected, added 70% ethanol and mixed well, added to the RNeasy 
MiniElute spin column and centrifuged for 15 seconds at 104 rpm, the flow-through were 
discarded. 700 μL RW1 buffer was added to the RNeasy MiniElute spin column and centrifuged 
for 15 seconds at 104 rpm. The flow-through was discarded and 500 μL RPE buffer was added 
to the column and centrifuged for 15 seconds a 104 rpm. The flow-through was discarded and 
500 μL 80% ethanol was added to the column and centrifuging for two minutes at 104 rpm. The 
flow-through was discarded and the column centrifuged with open lid for five minutes at full 
speed to dry the membrane. At the last step the column was placed in a new collection tube and 
added 14 μL RNase-free water and centrifuged for one minute at full speed to elute the RNA. 
The RNA was stored at -80°C if not used immediately. 
   
Figure 3.2: Example of Agilent bioanalyzer output for an RNA sample. The sample from Patient 5 was isolated 
from activated PBMC in cell culture and used for rt-qPCR with activated cells. The RNA integrity number (RIN) 
of 9 reflects a high RNA quality (left panel). The simulated gel image for the sample shows two distinct bands for 
28S and 18S (right panel).  
The RNA quality was assessed by the Agilent Bioanalyzer, using the Agilent 6000 Pico kit 
according to manufacturer’s protocol (figure 3.2). The RNA concentration was determined by 




3.8  RNA isolation from whole blood 
 
Whole blood was collected in PAXgene blood RNA tubes, and the RNA was purified using a 
PAXgene blood RNA-kit from Qiagen, following the manufactures protocol. Briefly, whole 
blood was collected in PAXgene blood RNA tubes, washed and centrifuged for 10 minutes at 
3000-5000 x g, the pellet resuspended in 350 μL resuspension buffer and transferred to a 
microcentrifuge tube. 40 μL Protein kinase K and 300 μL binding buffer was added to the tube 
and incubated for 10 minutes at 55°C using a shaker-incubator at 400-1400 rpm. The lysate was 
directly transferred to a PAXgene shredder spin column and centrifuged for 3 minutes at 14 000 
rpm. The supernatant of flow-through was transferred to a micro centrifuge tube, added 350 
pure ethanol μL (96-100%), centrifuged briefly, loaded on a PAXgene RNA spin column and 
centrifuges for 1 minute at 8000-20000 x g. Then, 350 μL wash buffer was added to the column, 
centrifuged and the flow-through discarded. 10 μL DNase was added to 70 μL DNA digestion 
buffer in a microcentrifuge tub, mixed and centrifuged briefly, before 80 μL of the residual 
liquid was added to the PAXgene RNA spin column and placed on the bench for 15 minutes. 
350 μL wash buffer was added to the column and centrifuged. The following step was then 
performed twice: the spin column was placed in a new processing tube and 500 μL wash buffer 
was added and the column, centrifuged, the flow-through discarded. The PAXgene RNA spin 
column was placed in a new microcentrifuge tube, added 40 μL elution buffer and centrifuged. 
Further, the eluate incubated for five minutes at 65°C and was immediately placed on ice. The 
RNA was stored at -80°C if not used immediately. 
 
3.9  Real-time quantitative PCR of candidate genes in the mTOR 
signaling pathway 
 
Whole blood was collected in PAXgene blood RNA tubes, and the RNA was purified using a 
PAXgene blood RNA-kit from Qiagen (section 3.8). For the cDNA synthesis the manufactures 
protocol for the RT2 first strand kit in format E was followed. A genomic DNA elimination mix 
was made, containing RNA (400 ng), 2 μL buffer GE and RNase-free water to a total volume 
of 10 μL. This was further incubated for five minutes at 42°C and immediately placed on ice 
for at least 1 minute. A reverse-transcription mix was made containing: 4 μL 5x BC3 buffer, 1 
μL control P2, 2 μL RE3 reverse transcriptase mix and 3 μL RNase-free water to a total volume 
of 10 μL for each sample. The reverse-transcription mix was added to the genomic DNA 
elimination mix to a total volume of 20 μL and mixed well. The mix incubated at 42 °C for 15 
minutes and the reaction was stopped by incubation at 95 °C for 5 minutes. 91 μL RNase-free 
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water was added to each reaction and mixed well by pipetting. The reaction was placed on ice 
in prior to proceed following the real-time PCR protocol in format E. PCR components mix 
was made in 5 mL tubes, containing: 650 μL 2x RT2 SYBR green mastermix, 102 μL cDNA 
synthesis reaction and 548 μL RNase-free water to a total volume of 1300 μL. For each 384-
well custom RT2 profiler PCR array, four samples were added in the amount of 10 μL to each 
well, analyzing 96 genes per sample including housekeeping genes, genomic DNA control, 
reverse-transcription control and positive PCR control. The plate was sealed and centrifuged at 
1000 g for 1 minute to remove bubbles. The plate was run in an ABI prism 7900HT sequence 
detection system using the following program: 95 °C for 10 minutes then 40 cycles of 95°C for 
15 seconds and 60°C for 1 minute. 
 
3.10 Real-time quantitative PCR of chosen genes 
 
RNA was purified using RNeasy micro plus kit from Qiagen, following the manufactures 
protocol (section 3.7). Further the Superscript III First-Strand Synthesis System for rt-PCR kit 
from Thermo Fisher was used to synthesize cDNA from RNA, following the manufactures 
protocol. For the first-strand synthesis a master mix was made for each sample containing: 0.35 
μL random hexamer (50 ng/ μL), 0.35 μL oligo(dT)20 (50 μM), 0.35 μL dNTP mix (10 mM), 
0.5 μL DEPC-treated water. 5 μL RNA from each sample was added and mixed by pipetting to 
a total volume 6.5 μL before incubating at 65 °C for 5 minutes. For the cDNA synthesis a master 
mix was made, each sample containing: 1 μL RT-buffer (10x), 2 μL MgCl2 (25mM), 1 μL DTT 
(0.1 M), 0.5 μL RNase out (40 U/ μL), 0.5 μL SuperScript III RT (200 U/μL), 1.5 μL DEPC-
treated water. 6.5 μL of the cDNA synthesis a master mix was added to the mix containing 
RNA to a total volume of 13 μL. The samples were run at the following program in a thermal 
cycler: 25°C for five minutes, 50°C for 60 minutes, 55°C for 15 minutes, 70°C for 15 minutes. 
Each sample was diluted 1:1 with DEPC-treated water and used for rt-qPCR. Rt-qPCR was 
performed using TaqMan gene expression assay. For each sample a mix of 1.65 μL 
probe/primer, 1.65 μL TaqMan enzyme (2x), 9.35 μL DEPC-treated water was added to 5 μL 
of the RNA sample (1:2 in DEPC-treated water).  The reaction mixture was transferred in 
triplicates to a clear 384 well plate, 10 μL to each well. A negative control was prepared for 
each gene expression assay and a housekeeping gene (B2M) was added to each sample. The 
plate was run in the ABI prism 7900HT sequence detection system at the following grogram: 





3.11 Flow cytometry  
 
The PBMC from cell culture was collected at day 5 and directly centrifuged at 300 x g for 10 
minutes (section 3.6). The supernatant was collected for later use (ELISA), and the pellet 
resuspended in 1mL PBS with dead cell stain and incubated for 20 minutes in room 
temperature. After incubation the cells were washed with 1 mL flow cytometry buffer (PBS 
with 0.5% BSA) and centrifuged at 300 x g for 10 minutes at 4 °C. The supernatant was 
removed, and the pellet resuspended in 100 μL flow cytometry buffer (PBS with 0.5% BSA) 
and added Fc block (0.5 mg/mL) for 20 minutes in room temperature before washed as 
previously described. The supernatant was removed, and the pellet resuspended in 100 μL flow 
cytometry buffer (PBS with 0.5% BSA). The cells were then stained with surface markers (table 
3.1). After incubating for 20 minutes at 4°C protected from light the cells were washed with 2 
mL flow cytometry buffer (PBS with 0.5% BSA) by centrifuging 300 x g for 10 minutes at 4 
°C. To stain with the intracellular markers, fixation and permeabilization was performed by the 
anti-human FoxP3 staining set, following the manufacture´s protocol. The cells were added 1 
mL perm/fix buffer and incubated at 4 °C protected from light overnight. The day after, the 
cells were washed with 1 x permeabilization buffer by centrifuging 500 x g for 5 minutes at 20 
°C, the supernatant discarded, and the cells resuspended in 100 μL permeabilization buffer. The 
cells were stained with antibodies against the intracellular markers FoxP3 and Helios (table 
3.1), and incubated for 30-60 minutes at 4 °C. Further the cells were washed with 1 x 
permeabilization buffer by centrifuging 500 x g for 5 minutes at 20 °C and kept on ice until the 
flow cytometry was performed using the BD LSR Fortessa, at the Flow Cytometry Core 
Facility, Department of Clinical Science, University of Bergen. To analyze the results FlowJo 







Table 3.1: Flow cytometry panel. Overview of targets, fluorochromes, dilution factor and wavelengths used for 
excitation and collection of emittances. 




Filter for emittance (band 
pas) 
CD3 V500 1:20 407 670/30 
CD4 Alexa Fluor 700 1:160 640 730/45 
CD8 PerCP-Cy5.5 1:20 488 695/40 
CD25/IL2RA PE-Cy7 1:40 561 780/60 
CD45RA APC-H7 1:80 640 780/60 
CD152/CTLA-4 BV421 1:20 407 450/50 
CD39/ENTPD-1 PE 1:500 561 582/15 
CD31/PECAM-1 BV785 1:160 407 780/60 
CD304/Neuropilin-1 BV650 1:80 407 670/30 
FoxP3 PE-CF594 1:10 561 610/20 
Helios/IKZF2 APC 1:40 640 670/14 
Dead cell stain q-dot585 1:1000 407 585/42 
CFSE FITC 1:10 488 530/30 
 
 
3.12 Cytokine enzyme-linked immunosorbent assay (ELISA) 
ELISA was used to quantify the amount of IFN- γ in the supernatant from the activated PBMC 
harvested for flow cytometry (section 3.11), using an ELISA MAX Deluxe set for Human IFN- 
γ delivered from BioLegend, following the manufacture´s protocol. All chemicals were diluted 
as described in the manufacture´s protocol. 
Briefly, supernatant was collected from the cells in cell culture, both untreated and treated with 
rapamycin. At day one, a 96 well plate was coated with 100 μL capture antibody (1:200), sealed, 
and incubated over night at 2°C-8°C. The day after, all reagents were brought to room 
temperature before use and the coated plate washed with at least 300 μL washing buffer. 200 
μL assay diluent A (1:5) was added to each well to block non-specific binding and reduce 
background, the plate was sealed and incubated at room temperature for 1 hour with shaking.  
The standard cure was made with 1000 μL of the top standard diluted in assay diluent A (1:5) 
to a concentration of 500 pg/mL. A six two-fold serial dilution of the 500 pg/mL top standard 
was performed, and assay diluent A diluted (1:5) was used as the zero standard at 0 pg/mL.  
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The plate was washed 4 times, and 100 μL of each standard and sample was added to the plate 
in triplets, the samples were diluted in assay diluent A (1:5) with the dilution factors: 1, 1:25 
and 1:100. The plate was sealed and incubated at room temperature for 2 hours with shaking. 
The plate was washed 4 times with wash buffer, before adding 100 μL detection antibody 
(1:200) and incubated for 1 hour at room temperature with shaking. The plate was washed 4 
times with washing buffer and 100 μL Avidin-HRP solution (1:1000) was added to each well, 
sealed and incubated for 30 minutes in room temperature with shaking. Further the plate was 
washed 5 times, where it was soaked in wash buffer for 30 seconds between each wash. Freshly 
mixed TMB substrate solution was added to each well in the amount of 100 μL and incubated 
for 20 minutes protected from light. Wells containing IFN-γ now turned blue in color. To stop 
the reaction, 100 μL stop solution (H2SO4, 0.2 M) was added to each well, which turned the 
positive blue wells into yellow. The absorbance was then read at 450 nm within 15 minutes 
using Spectramax Plus. The IFN- γ concentration (pg/mL) was calculated from four parameter 
logistic (4-PL) curve-fit. 
 
3.13 Statistical analysis 
 
For statistical analysis of the rt-qPCR, flow cytometry and ELISA results, both non-parametric 
two-tailed Mann-Whitney test and parametric paired t-test was used. A non-parametric two-
tailed Mann-Whitney test was chosen in the comparison of patients and controls. Two-tailed 
nonparametric tests were chosen due to the low number of samples avoiding an assumption of 
a normal distribution, using the median value for the central tendency. In the comparison of 
treated and untreated samples a two-tailed paired parametric t-test was chosen, as a non-
parametric paired test is not suitable for N<5 with a significance threshold set at P<0.05. Results 
were found significant if P < 0.05 in the flow cytometry results, ELISA results and the rt-qPCR 
of activated cells. The rt-qPCR results with resting cells were found significant if P <0.01 to 





4.1  Real-time quantitative PCR assessment of genes in the 
mTOR signaling pathway in resting cells 
 
Isolated RNA from whole blood from patients (patient 1 and 7-12) and controls (control 6-13) 
were assessed for the expression level of genes in the mTOR signaling pathway (86 genes), all 
genes are listed in appendix (table A.4). The plates used for rt-qPCR were analysing genes in 
the mTOR signalling pathway, commercially available by Qiagen. The RNA from patients and 
controls had a RIN-values ranging from 7.8-9.1 and concentration in the range 63-164 ng/μL. 
Each sample was only analysed once for gene expression due to limited material available. The 
cut-off was defined at 40 cycles and the threshold at 0.2; those samples who were undetectable 
were removed. For the gene Insulin, only three of the controls (6,7 and 9) and three of the 
patients (6,8 and 9) reached the threshold; the others were therefore removed. This was also 
observed in other samples for nine other genes, but all samples passed the internal controls 




Figure 4.1: Comparing the fold change in patients and controls. The fold change were calculated using the 2-
Ct-formula, showing a relative expression level of the target. The bars illutrates the median fold change value 
and the error bars shows the 95% CI. (-) means that the cells are not treated with rapamycin. The p-value was 
calculated using non-parametric Mann-Whitney test, samples were found significant if P<0.01. For insulin only 
3 of the controls (6,7 and 9) and 3 of the patients (6,8 and 9) reached treshold, the others are therefore removed. 
 
For each sample and gene, the fold change was calculated using the 2-Ct-formula, where the 
fold change for the housekeeping gene is taken into account. No significant difference in 
controls or patients was observed for any of the genes using the RT2Profiler PCR Array Data 
Analysis Webportal, nor calculations of the p-value in GraphPad, using a non-parametric 
Mann-Whitney test (table 4.1). No differences were observed in the expression of genes 
comparing patients and controls, but a slightly increased expression could be seen for mTOR 
(P=0.488) in the patients (figure 4.1 a, table 4.1). For Insulin (P=0.700), one of the patients had 
a notable expression (figure 4.1 b, table 4.1); this was also observed for Raptor (P=0.624) 
(figure 4.1 d, table 4.1). Some of the other genes PTEN (P=0.625), Akt (P=0.625) and PI3K 
(P=0.938) (figure 4.1 c, e, f, table 4.1) which are also important in the regulation of mTOR [91], 
did not show any changes in the expression comparing patients and controls.  
Table 4.1: Comparison of the fold change ratio of the relative gene expression between patients and controls 
in some of the genes in the mTOR signaling pathway. 
















mTOR 1.22 0.0163 0.035,  
0.007 
0.0193 0.035,  
0.001 
0.488 
Insulin 3.41 1.2•10-6 6.27•10-6,  
-4.13•10-6 
1.7•10-6 5.22•10-5,  
-4.08•10-5 
0.700 
PTEN 0.94 0.0222 0.041,  
0.013 
0.0252 0.036,  
0.015 
0.625 
Raptor 1.35 0.0042 0.007,  
0.002 
0.0044 0.016,  
-0.002 
0.624 
Akt 0.85 0.0435 0.052,  
0.030 
0.0379 0.049,  
0.023 
0.625 
PI3K 0.94 0.0134 0.020,  
0.010 
0.0135 0.019,  
0.010 
0.938 





PDPK1 1.43 0.0148 0.025,  
0.011 
0.0205 0.053,  
0.007 
0.266 
*Non-parametric Mann-Whitney test, results were found significant if P < 0.01. 
 
When comparing the mean foldchange in patients and controls calculated by RT2 Profiler PCR 
Array Data Analysis Webportal, Insulin had a fold change (patient/control) 3.41 greater for the 
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patients than for the controls, indicating a 3.41 times larger expression in the patients (table 
4.1). Even though only one of the patients had a great expression of Insulin, this gene was 
chosen for further analysis in the assessment of gene expression using RNA from activated cells 
treated or untreated with rapamycin (section 4.2). The other genes had a fold changes 
(patient/control) in the range 0.62-1.43 (table 4.1). mTOR and CTLA-4 was also chosen for 
further analysis, as mTOR is the target of rapamycin, and CTLA-4 is important for the 
suppressive function in Treg [58, 91]. Fold change (patient/control) for all genes included are 
listed in appendix (table A.4). 
 
4.2  Real-time quantitative PCR assessment of chosen genes in 
activated PBMC treated with rapamycin in cell culture 
To assess the expression of the genes mTOR, Insulin and CTLA-4 in PBMC activated with anti-
CD3 and -CD28 and treated with rapamycin in cell culture, RNA was isolated from PBMC 
after 5 days in cell culture from patient and control 1-5. The RNA used had a RIN-values 
ranging from 3.7-9.0 and concentrations ranging from 1.7-96.6 ng/μL. When looking at the 
resulting raw Ct values, the expression of the housekeeping gene B2M, run in the same tube as 
for candidate genes, was observed in all samples with a threshold put to 0.3540 Ct. For the 
genes of interest, the thresholds for CTLA-4 and Insulin were put to 0.0147 Ct, and for mTOR 
to 0.0195 Ct, reflecting low expression in the selected genes. Due to the low expression of 
Insulin in the treated samples for control 1 and patient 2, they did not reach threshold and was 
therefore removed.  
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Figure 4.2: Normalized gene expression comparing treated and untreated controls and patients. The lines 
show the change in gene expression, comparing untreated (-) and treated (+) samples. The p-value were calculated 
using a parametric paired t-test, samples were found significant if P<0.05. For Insulin, patient 2 and control 1 
were removed since they did not reach treshold. 
 
To assess the difference in treated and untreated samples for patients and controls a normalized 
gene expression was used (figure 4.2). When comparing the untreated and treated samples, in 
the patient and control group, only the expression of CTLA-4 in the patients (untreated patients 
median: 0.25± 0.47, 0.05 median treated patients: 0.20± 0.32, 0.016, P=0.023) had a significant 
decrease when treated with rapamycin (figure 4.2 c). However, a trend was observed, for most 
samples, where the expression of the respective genes decreased after addition of rapamycin. 
Interestingly, two of the patients had an increase in the expression of mTOR when treated with 
rapamycin (figure 4.2 a). This was also observed for one control in the expression of Insulin 
(figure 4.2 b) and CTLA-4 (figure 4.2 c).  
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Figure 4.3: Gene expression comparing control and patient. The bars show the gene expression in treated 
samples (+) and the error bar shows the 95% CI, untreated samples are represented by the stipled line at 1 (-). 
The p-value were calculated using a non-parametric Mann-Whitney test, samples were found significant if P<0.05. 
For Insulin patient 2 and control 1 were removed since they did not reach treshold. The column shows the median 
with 95% CI. 
To further look at the effect of rapamycin on the expression of the respective genes, the gene 
expression in the treated samples for controls and patients was normalized relative to the 
untreated samples. For all the genes investigated, the spread between individuals were relatively 
large and the differences between APS-1 patients and controls were small for mTOR and CTLA-
4, while a larger difference occurred for Insulin (figure 4.3). Still, a trend was observed, that 
expression level of all three genes were decreased in the treated samples, except for Insulin in 
the treated controls where the median showed an increase (figure 4.3 c). There was also some 
samples that did not follow the trend, with an increased expression after the treatment with 
rapamycin. However, no significant difference was observed comparing the patients and 
controls using a non-parametric Mann-Whitney test, where the difference was found significant 
if P<0.05.  
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4.3 Validation of rapamycin concentration and assessment of 
activated cells and Treg with flow cytometry 
 
Flow cytometry was used to determine the optimal concentration of rapamycin and to assess 
the frequency of activated cells, defined as CD3+ CD4+ CD25+, and Treg, defined as CD25high 
FoxP3+, in patients and controls. PBMC was isolated from patient and control 1-5, activated 
with anti-CD3 and -CD28, treated with rapamycin in cell culture for five days, and stained with 
extracellular and intracellular markers prior to flow cytometry. 
 
4.3.1 Gating strategy 
 
The gating strategy is shown by a representative sample in figure 4.4 (activated cells), 4.5 
(subpopulations within activated cells) and 4.6 (subpopulations within Treg). All samples 
followed the same gating strategy. 
 
Figure 4.4: Gating strategy in FlowJo, untreated control 1. A plot of forward scatter area versus side scatter 
area is used to gate for lymphocytes (a), further gating for singlets (b) with forward scatter area versus forward 
scatter height. Live cells (c) were gated with forward scatter area versus BV570 fluorescence. To gate for T cells, 
defined as CD3+ (d) a gate with forward scatter area versus BV510 was made. Further a gate with PerCP-Cy5-5 
versus Alexa Fluor 700 was used to gate for CD4+CD8- cells (e), and finally activated cells defined as CD3+ CD4+ 




Figure 4.5: Gating strategy in FlowJo, populations of cells within CD3+ CD4+ CD25+ cells, untreated control 
1. To gate for subpopulations within activated cells, defined as CD3+ CD4+ CD25+, the gate for CD3+ CD4+ 
CD25+ cells defined in figure 4.4 (f) was used for a)-f). The respective markers for a) – f) at the y-axis was gated 
with PE-Cy7 to define subpopulations. To gate for Treg, defined as CD3+ CD4+CD25highFoxP3+(g) the gate for 




Figur 4.6: Gating strategy in FlowJo, populations of cells within Treg, defined as CD25high FoxP3+ cells, 
untreated control 1. To gate for subpopulations within Treg, the gate for CD25high FoxP3+ defined in figure 4.6 
(g) was used. The respective markers for a) – e) at the x-axis versus PE-TR_ECD was used to gate for 
subpopulations. 
 
4.3.2 Determination of rapamycin concentration 
 
In order to investigate the effect of rapamycin on PBMC from patients and controls, an 
appropriate concentration of the drug had to be determined. Two titration lines were prepared, 
and flow cytometry was used to analyze the proliferation of the cells. We wanted to choose a 
concentration with an inhibiting effect but that would not kill too many cells, due to the low 
number of cells available. The number of cells is listed in appendix (A.3). The first titration line 
included the concentrations; 0.05 nM, 0.1 nM, 1 nM and 2 nM performed on control 14, and 
the second titration line included 2 nM and 4 nM performed on patient and control 1. The choice 
of 4 nM for use in all samples was based on the small difference between the cells ability to 
divide compared with the concentration at 2 nM. Results are listed in appendix (A.5). 
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4.3.3 Cell proliferation after treatment with rapamycin 
 
When comparing the percentage of live cells in samples treated with rapamycin with the 
respective untreated sample, a decreasing trend was observed for the treated samples. There 
was one odd control, in which a small increase was observed (figure 4.7 a). The same was 
observed for the proliferation index (figure 4.7 b), except for one of the patient samples, which 
had an increase in the cell proliferation when treated with rapamycin, compared with the 
untreated sample. When performing a parametric paired t-test, only the proliferation in the 
controls had a significant decrease after treatment with rapamycin. Still, a trend was observed 
in most samples, with a decrease in live cells and proliferation after treatment with rapamycin.  
 
 
Figure 4.7: Frequency of live cells and proliferation index for controls and patients, treated with rapamycin 
and untreated. The lines shows the change in frequency comparing samples treated with rapamycin (+) and 
untreated (-). The p-value were calculated using a parametric paired t-test, samples were found significant if 
P<0.05. 
 
The median proliferation index and median frequency of live cells show the same trend as 
mentioned above (table 4.2). The median frequencies of live cells in activated cells and Treg are 
listed in appendix (A.6 and A.7).  
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Table 4.2: Median (range) proliferation index and median frequency of live cells for samples treated with 
rapamycin (+) and untreated (-) samples, for patients and controls.  










































*parametric paired t-test, results were found significant if P < 0.05. 
 
When all untreated samples were compared with the treated samples, patients and controls 
combined using a parametric paired t-test, the frequency of live cells (untreated samples 
median: 42.45 (95% CI: 68.8, 30.14), treated samples median: 35.55 (95% CI: 58.2, 24.10), P= 
0.042) and the proliferation (untreated samples median: 1.47 (95% CI: 1.95, 1.38), treated 
samples median: 1.24 (95% CI: 1.44, 1.13), P= 0.001), had a significant decrease in the treated 
samples, indicating that rapamycin had an effect on both cell death and the cells ability to 
proliferate.  
 
4.3.4 The effect of rapamycin in subpopulations of CD4+ cells 
upon activation 
To assess the level of the chosen markers within activated cells, the gates in figure 4.5 was 
used. For all markers the median frequency of cells decreased in the samples treated with 
rapamycin, for both patients and controls, where some reached statistical significance (table 
4.3). In both patients (P=0.0193) and controls (P=0.0357) the frequency of activated cells 
(CD3+CD4+CD25+) had a significant decrease when treated with rapamycin. This was also 
observed for the markers CD31 and CD39 (table 4.3). However, the markers CD304 and 
CTLA-4 only had a significant decrease in the patients when treated with rapamycin (table 4.3). 
The other markers Helios and FoxP3 also had a decreased frequency when treated with 
rapamycin, but not reaching statistical significance.   
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Table 4.3: Median frequency of cells within CD3+CD4+CD25+ for samples treated with rapamycin (+) and 
untreated (-) samples, for patients and controls.  

















































Markers within CD3+CD4+CD25+ 






















































*Parametric paired t-test, results were found significant if P < 0.05. 
 
Comparison of the difference between untreated and treated cells in patients and controls was 
performed by normalizing the samples treated with rapamycin relative to the untreated sample 
(table 4.4). This was done due to a great variation observed among the samples. 
Table 4.4: Comparison of median difference between untreated (-) and treated (+) cells in patients and 
controls for the respective markers. 
Markers Median difference between 
untreated (-) and treated (+) 
cells, controls  
(95% CI) 
Median difference between 



















































*Non-parametric Mann-Whitney test, results were found significant if P < 0.05. 
 
The difference between the treated and untreated samples in the controls compared with the 
patients was analyzed by performing a non-parametric Mann-Whitney test, where significance 
was shown for CD31 (P=0.016) and CD39 (P= 0.032) (table 4.4). This indicates a greater 
decrease in the frequency of CD31+ cells in the controls, and a greater decrease in the frequency 
of CD39+ cells in the patients (table 4.4). None of the other markers had a significant difference 
in the comparison of patients and controls, where all markers had a decreasing trend in the 
samples treated with rapamycin. When gating for activated cells within CD3+ CD8+ cells, the 
same pattern was observed (data not shown), indicating that rapamycin suppresses both 
CD+CD25+ and CD8+ T cells. 
 
4.3.5 The effect of rapamycin on Treg and subpopulations of cells   
within Treg 
 
To assess the frequency of Treg cells, the gate in figure 4.5 g) was used. The respective markers 
within Treg, were gated as shown in figure 4.6 a)-e). Comparison of the percentages of the 
respective markers in cells treated with rapamycin and untreated cells was performed using a 
parametric paired t-test (figure 4.8 b, and 4.9). For most samples a trend was observed, the 
median frequency of cells decreased after treatment with rapamycin, where some of the markers 
reached a significant decrease (figure 4.9, table 4.5). 
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Figure 4.8: Comparison of the frequency of Treg, defined as CD25high FoxP3+, in PBMC treated with 
rapamycin and untreated for patients and controls. a) Shows the gating in FlowJo for both treated (+) and 
untreated (-) samples in control and patient 1.  b) Shows the change in frequency in patients and controls, 
illustrated by the lines (upper part). The bars shows the median frequency of positive cells and the error bar shows 
the 95% CI (lower part). The p-value were calculated using a parametric paired t-test, samples were found 
significant if P<0.05.  
 
When gating for the Treg population (figure 4.8 a), great variations could be seen among the 
different samples. Interestingly, for two of the patients and two controls, the frequency of Treg 
only had a small decrease when treated with rapamycin, and for one control and one patient 
only a small increase occurred. The rest of the samples had a more distinct decrease of Treg 
when treated with rapamycin (figure 4.8 b). When comparing the median for controls and 
patients treated with rapamycin a greater decrease in frequency of Treg was observed in the 








Figure 4.9: Comparison of the frequency of positive cells for the respective markers within Treg (CD25high 
FoxP3+)  in PBMC treated with rapamycin and untreated for patients and controls.  The respective markers 
within Treg are represented in a) – e). The lines between treated and untreated samples shows the change in 
frequency (left and middle part), the bars shows the median frequency of positive cells within the respective 
population and the error bar shows the 95% CI (right part). (+) means that the sample were treated with 
rapamycin and (-) means that the sample were untreated. The p-value were calculated using a parametric paired 
t-test, samples were found significant if P<0.05.  
The frequency of CD31+ cells, a marker which expression indicates a recent thymic emigration 
[57], had great variation among the controls, whereas the frequency in the patients samples had 
less variation. However, for both control and patients a significant decrease of CD31 was 
observed when treated with rapamycin (figure 4.9 a, table 4.5). For Helios, a marker suggested 
for nTreg [48], no great difference in the controls were observed, where the median had a slight 
increase when treated with rapamycin. In the patients, on the other hand, the samples had a 
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significant decrease in frequency when treated (figure 4.9 e, table 4.5). Interestingly, for these 
two markers most samples seemed to only have a small decrease when treated with rapamycin. 
When comparing the frequency of CD304 (neuropilin-1), a marker for nTreg. [56], a great 
variation among the samples occurred in both the patients and controls, also her both patients 
and controls had a significant decrease in frequency when treated with rapamycin (figure 4.9 b, 
table 4.5). The frequency of CD39, a marker with inhibitory properties expressed on Treg [60], 
had a greater decrease in the patient samples treated with rapamycin compared with the treated 
controls, where the patients had a higher expression in the untreated sample compared with the 
untreated control (figure 4.9 c, table 4.5). But both patients and controls had a significant 
decrease.   
When staining the cells, CTLA-4 staining was performed prior to permeabilization; therefore, 
only extracellular CTLA-4 was detected. The expression of this marker varies in both controls 
and patients, where the patient samples had a significant decrease when treated with rapamycin. 
The control also had a decreased expression, but not reaching statistical significance (figure 4.9 
d, table 4.5).  
Table 4.5: Median frequency of cells within Treg  (CD25high FoxP3+) for samples treated with rapamycin (+) 









































































*Parametric paired t-test, results were found significant if P < 0.05. 
 
When performing the same comparison in patients and controls for the markers in Treg as 
described for activated cells (section 4.3.4), none of the markers had a significant difference in 
the frequency comparing controls and patients (table 4.6). However, a greater decrease in the 
controls for CD31 and a greater decrease in the patients for CD39 was observed in the treated 
samples, the same trend as was observed within activated cells (section 4.3.4).  
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Table 4.6: Comparison of median difference between untreated (-) and treated (+) cells in patients and 
controls in the respective markers within Treg (CD25high FoxP3+) 
Markers within 
CD25high FoxP3+ 
Median difference between 
untreated (-) and treated (+) 
cells, controls 
(95% CI) 
Median difference between 





























*Non-parametric Mann-Whitney test, results were found significant if P < 0.05. 
A parametric paired t-test was performed for the markers within Treg (CD25high FoxP3+) cells 
in all untreated samples, both controls and patients together, paired with their treated samples. 
This showed a highly significant decrease in frequency for all markers (table 4.7), and indicates 
that the frequency of cells with the respective markers, within Treg, decreases when treated with 
rapamycin. 
Table 4.7: Comparison of positive cells with the respective markers within CD25high FoxP3+ cells for all 
untreated and treated samples, including both patients and controls.  
Markers within 
CD25high FoxP3+ 
Median frequency (%) in 
untreated samples (-) 
(95% CI) 
Median frequency (%) in 




























*Parametric paired t-test, results were found significant if P < 0.05. 
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4.4  IFN-γ production by activated PBMC treated with 
rapamycin in cell culture analysed by ELISA 
 
The supernatant from the activated PBMC was collected when the cells were harvested for flow 
cytometry, to assess the production of IFN-γ, a proinflammatory cytokine produced by 
activated T cells [64]. To determine the concentration of IFN-γ, a standard curve was made 
(figure 4.9), with a top concentration at approximately 500 pg/mL using ELISA MAX Deluxe 
kit.  
 
Figure 4.9: Standard curve. A six two-fold serial dilution of the 500 pg/mL top standard was performed to make 
the standard curve. The x-axis presents the average concentration and the y-axis the average optical density (O.D).  
 
There was a great variation among the samples, and some samples needed to be diluted with 
the dilution factors 1:25 and 1:100 to fit the standard curve. Control 3 did still not fit in the 
standard curve; hence the measured amount is likely to be much higher than detected. 
Conc








4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2





Figure 4.10: The adjusted concentration of IFN-γ (pg/mL) for each individual sample. The bars present the 
mean adjusted concentration of IFN-γ in each individual sample. (+) means that the sample were treated with 
rapamycin and (-) means that the sample were untreated. The bars marked with arrows illustrates the samples 




Figure 4.11: Comparison of the amount IFN-γ in treated and untreated samples for controls and patients 
using log-values. The lines show the change in the amount of IFN-γ, comparing untreated samples (-) and samples 
treated with rapamycin (+). Using a parametric paired t-test comparing the amount of IFN-γ in patients (-) and 
(+) (P=0.325), and control (-) and (+) (P=0.343) gave no significance, results were found significant if P < 0.05.  
 
The results illustrated in figure 4.10 indicates great variation between all samples in both 
controls and patients. Using a parametric paired t-test comparing the amount of IFN-γ in 
patients treated with rapamycin and untreated (untreated patients median:157.5 (95% CI: -
31529, 75045) treated patients median: 35.6 (95% CI: -280.4, 817.4) P=0.325), and control 
treated with rapamycin and untreated (untreated controls median: 442.3 (95% CI: -20653, 
61105), treated controls median: 7.164 (95% CI: -24735, 57551), P=0.343) gave no significant 
decrease. When performing the same test with all samples treated with rapamycin, paired with 
their respective untreated sample, combining patients and controls, the result gave a no 
significant decrease in the amount  of IFN-γ in the treated samples (untreated samples median: 
299.9 (95% CI: -4810, 46794), treated samples median: 34.27 (95% CI: -8597, 25273), 
P=0.223). However, a trend was observed, where all samples treated with rapamycin had a 





APS-1 is a rare disease characterized by the three main manifestations of Addison´s disease, 
hypoparathyroidism and chronic mucocutaneous candidiasis. In addition, there are several other 
symptoms observed affecting organs and tissue of both endocrine and non-endocrine origin. 
The present treatment accordingly includes hormone-replacement, oral azole drugs and in some 
cases the immune suppressants, such as CsA. These patients suffer from an earlier death, and 
lower quality of life compared to the general population [79, 122]. In the treatment regimens 
there are challenges due to interactions and drug resistance, and there is a great need of studies 
on new targeted treatments of APS-1. Studies have found that the differentiation of the Treg 
lineage seems to be affected in these patients [33], in addition to a reported lower frequency of 
Treg in APS-1 patients in comparison with age-and sex-matched healthy controls [81]. An 
important regulator of metabolism and proliferation in the development of Treg is the gene 
mTOR, encoding a protein kinase with the same name [48]. The mTOR inhibitor rapamycin is 
mainly used to prevent allograft rejection but is suggested to have effect in autoimmune 
diseases as well. The mechanism of action has similarities with CsA as they both bind to FKBP-
12, but instead of inhibiting TCR-induced calcineurin activity, rapamycin inhibits mTORC1 
[103], where studies have indicated that rapamycin promotes the generation of Treg cells or 
enhances their activity [48]. 
 
5.1 Establishing an experimental cell-based system to investigate 
the effect of rapamycin on PBMC 
 
In this project we succeeded to establish a cell-based system to assess the effect of rapamycin 
on PBMC from APS-1 patients compared to healthy controls. However, the setup had some 
limitations, the major ones being limited patient material and few patients. For example, even 
though we already form the beginning had a limited amount of PBMCs from each individual, 
we had to use frozen cells and we chose to use a magnetic bead-based kit to remove dead cells 
prior to the cell culture. This introduced even larger challenges with low and variable numbers 
of cells, but this procedure was considered a necessity to further be able to assess the effect of 
rapamycin on cell death and proliferation. To simulate an activation of the cells, plate bound 
anti-CD3 and -CD28 were added, before the cells were to be further treated with rapamycin in 
cell culture. Based on the response in cell culture and the assessment by flow cytometry, the 
activation of the cells was successful also in the presence of rapamycin. Activation using anti-
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CD3 and CD28 was performed because this is known to have a large T cell specific stimulation 
[123], which we needed in our approach. 
 
As rapamycin has low solubility in water [112], DMSO were used as dissolvent. However, 
there may be some complications with diluting rapamycin in DMSO. Studies has found that the 
concentration of compounds diluted in DMSO were variable after distribution of the diluted 
stock solution, and that the concentration of the diluted compound was below the expected 
value [124]. We were unable to assess the concentration of rapamycin after each dilution, which 
may affect the results due to a possible variable concentration in the different assays. Also, a 
distribution of the stock solution was considered necessary to avoid the need of freezing and 
thawing, which may affect the stability of the compound.   
 
When performing this experiment for the various samples, great variation occurred. This may 
be due to biological variations or the performance on the day it was completed, although the 
attempt was made to carry out the experiment equally. We took care to always include one 
patient and one control each time we performed the cell assay. Despite these limitations we 
succeeded in the development of a protocol to further be used to assess the effect of rapamycin 
or other drugs on PBMC.  
 
5.2  A possible immunosuppressive effect of rapamycin in 
controls and patients 
 
To assess the effect of rapamycin at RNA level, we first searched for candidate genes in the 
mTOR signaling pathway using rt-qPCR with resting blood cells that were not treated with 
rapamycin. No great differences in the gene expressions comparing patients and controls were 
observed (figure 4.1), but mTOR was chosen for downstream applications, being the target of 
rapamycin. Furthermore, Insulin was chosen, as mTOR is dependent on stimulation of nutrients 
to be activated [91], and the fold change comparison of patients and controls showed a higher 
expression of Insulin in patients compared to healthy individuals. Finally, CTLA-4 was chosen 
as it is suggested to be crucial for the suppressive mechanisms of Treg [58].  
 
Only CTLA-4 in the patients had a significant change in the gene expression of activated cells 
treated with rapamycin for the chosen genes using rt-qPCR (figure 4.2 c). Still, a trend occurred 
for all genes in most samples, where the gene expression decreased when the cells were treated 
with rapamycin, in both patients and controls. However, there were exceptions where some 
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samples did not follow the trend, e.g. only 3/5 patients had a decrease in the expression of 
mTOR (figure 4.3 a). Interestingly, 2 patients had an increase in the expression of mTOR, hence 
one might speculate that some APS-1 patients may be resistant or less sensitive to treatment 
with rapamycin. Previous findings have shown a downregulation of mTOR after treatment with 
rapamycin, however that study were performed on other cell lines at a protein level [125]. A 
study in yeast suggested that mutations in mTOR and FKBP-12 can cause resistance to 
rapamycin treatment, by preventing an interaction between mTOR, FKBP12 and rapamycin 
[126]. Other studies have speculated on how different cells may be resistant or less sensitive to 
rapamycin, where rhabdomyosarcoma cancer cell lines were more sensitive than colon cancer 
cell lines [127]. Mutations or genetic variation in mTOR itself have not been investigated in 
these APS-1 patients.  
 
The expression of CTLA-4 decreased in most samples for both patients and controls, where only 
the patient samples had a significant decrease (figure 4.2 c). This corresponds with our 
observations at protein level using flow cytometry, where also only the patient samples had a 
significant decrease in the frequency of CTLA-4 (table 4.3, figure 4.9 d).  A study using flow 
cytometry identified that Treg had a higher expression of CTLA-4 after treatment with 
rapamycin [106], this do not correspond with our findings. However, in our study PBMC was 
used, hence not being able to assess the specific expression of CTLA-4 in Treg. Also, Insulin had 
a decreasing trend after the treatment with rapamycin, but two of the controls had an increase 
in the expression after treatment with rapamycin (figure 4.3 b). Notably, other studies have 
found that rapamycin increased insulin sensitivity in healthy men, and increased the insulin 
dependent glucose uptake [128]. There are factors that may affect the results. In the case of 
CTLA-4 expression, an increased expression has been observed after infection [129]. Another 
important factor is variable concentration and integrity of the mRNA used in this project, where 
low quality mRNA affects the cDNA synthesis, making the results less reliable. However, we 
only had the material that we got from the cell cultures and had to perform our analysis on this 
limited material. 
 
To assess the effect of rapamycin at the protein level, selected T cell markers were used for 
staining of activated PBMC treated with rapamycin from patients and controls prior to flow 
cytometry. CFSE staining was also performed prior to flow cytometry, to assess the effect of 
rapamycin on cell proliferation. We observed changes in the cells ability to proliferate in 
presence of rapamycin and a decrease in the number of live cells (figure 4.7). mTOR is crucial 
 64 
for cell proliferation and the prevention of autophagy; when cells are exposed for metabolic 
and therapeutic stress, such as the mTOR inhibitor rapamycin, autophagy and cell death can be 
observed [130]. In a related study looking at how rapamycin affects the proliferation in PBMC 
similar findings were noted, where PBMC was treated with 10 nM rapamycin in cell culture 
[131]. This suggests that the rapamycin treated cells had a reduced proliferative capacity 
compared with the untreated samples. However, no significant decrease in live cells were found 
after treatment with rapamycin in neither the controls nor the patients (table 4.2), but a 
significant decrease in the proliferation was observed in the controls, but not for the patients 
(table 4.2). In our study the concentration of rapamycin was 4 nM, where a higher concentration 
possibly could have given a larger decrease in live cells and proliferation. When including both 
controls and patients in the same statistics to compare the samples treated with rapamycin with 
the untreated, a significant decrease in live cells and proliferation occurred. This suggests that 
the number of samples in the patient and control group are too few to give enough statistical 
power.  
 
T cells are known to express CD25 upon activation, which has been shown to be suppressed by 
rapamycin upon CD3 activation [132]. This align with our results, where the frequency of 
activated cell (CD3+CD4+CD25+) had a significant decrease in both patients and controls when 
treated with rapamycin, indicating that rapamycin inhibited the activation of T cells in vitro. 
This was also observed for the markers CD31 and CD39, and for the markers CD304 and 
CTLA-4 a significant decrease occurred only in the patients (table 4.3). As only extracellular 
staining was used to assess the expression of CTLA-4, we were not able to assess the 
intracellular expression. It would be interesting to look further into this, as it is suggested that 
the intracellular expression of CTLA-4 in T cells is constitutive [133]. However, no large 
difference between APS-1 patients and controls were found when comparing the median 
difference between untreated and treated cells in patients and controls (table 4.4). This 
implicates that the immunosuppressive effect of rapamycin on PBMC were not more favorable 
in the controls than the patients, or vice versa. An exception to this was in the comparison within 
activated cells where the expression of CD31 and CD39 had a significant difference between 
the APS-1 patients and controls (table 4.4). CD31 had a larger decrease in the controls than in 
APS-1 patients (table 4.4), where the same trend was observed for this marker within Treg, but 
not reaching statistical significance (table 4.6). However, it is worth noticing that the untreated 
control samples had a higher frequency of CD31+ cells than in the APS-1 patients within 
activated cells. This observed lack in CD31 in the APS-1 patients, a marker for recently 
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emerged T cells [57], could possibly reflect a lack of AIRE expression in the thymus, as other 
studies have observed a possible impairment of Treg cells emerging from the thymus in APS-1 
patients [82]. For CD39 within activated cells, a larger decreased in the APS-1 patients occurred 
(table 4.4), also here the same trend was observed within Treg but not reaching statistical 
significance (table 4.6). This do not correspond with previous studies reporting that rapamycin 
gave an enhanced CD39 expression on iTreg, but these studies were performed with isolated 
CD4+ cells and Treg [134, 135].  In our study the amount of iTreg in the PBMC might not be 
large enough to show an increase in the expression of CD39. It would be interesting to look 
further into this phenomenon with isolated Treg.  
 
Our findings of a decreased amount of IFN-γ in all samples treated with rapamycin correspond 
with previous findings (section 4.4), where the production of IFN- γ decreased in PBMC in the 
presence of rapamycin [136]. IFN-γ is secreted by T cells such as TH1 [137], and Delgoffe et al. 
demonstrated that this T cell linage were dependent on mTORC1 to proliferate. Knockout of 
Rheb (an activator of mTORC1) in T cells decreased the differentiation of TH1 and TH17, both 
implicated in promoting autoimmune diseases [89]. However, it is worth noticing that a possible 
reduced proliferation of TH17 may not be beneficial for APS-1 patients, ass this T cell subset 
produces IL-17, a cytokine reported to be involved in clearing Candida infections, a condition 
many APS-1 patients suffer from [138].  
 
The decrease in both IFN-γ and CD39 within activated cells in all samples after treatment with 
rapamycin, possibly correspond with an observations in mice suggesting that IFN-γ+ CD4+ and 
CD8+ T cells both express CD39 [139]. We also observed that the frequency of activated CD8+ 
T cells decreased when treated with rapamycin, where a great decrease of CD8+CD39+ occurred 
(data not shown). One study have observed that CD8+CD39+ cells were associated with IFN-γ 
production [140]. However, we were not able to detect the IFN-γ producing cells, as the 
supernatant was collected for PBMC. 
 
A previous study have found a decreased level of Treg in PBMC in APS-1 patients compared 
with controls [81]. This do not correspond with our study where no large difference was 
observed, and patients had a larger frequency in the untreated sample compared with the 
controls. However, the cells in our study was incubated in cell culture for five days. 
Interestingly, the frequency of Treg, for three of the patients and controls, only had a small 
decrease when treated with rapamycin, whereas two of the patients and controls had a more 
 66 
distinct decrease (figure 4.8 b). Studies have found that rapamycin promotes expansion of 
functional Treg, in PBMC from both healthy controls and patients suffering from autoimmunity 
[141, 142]. We were not able to determine the exact effect of rapamycin on Treg in this regard, 
but it is worth noticing that Helios and CD31, suggested to be expressed on nTreg [48, 57], in 
both patients and controls illustrates a smaller decrease when treated with rapamycin than some 
of the other markers (figure 4.9 a and e). However, a significant decrease of CD31 occurred for 
both patients and controls in the treated samples, but only for the patients in the case of Helios 
(table 4.5). Studies have suggested that rapamycin favor the proliferation of nTreg [143]. 
However, the reliability of Helios as a marker for nTreg are under debate [144]. It is also 
interesting that CD304 apparently had a larger decrease than Helios and CD31 (figure 4.9 b), 
as it is also suggested to be a marker for nTreg [56]. 
 
Although some of the results reached a statistical significance, the reliability of these findings 
is weak, with the low number of samples in the patient and control group. Also, methods such 
as flow cytometry requires great caution in the analysis as small adjustments has a great impact, 
especially with low number of cells, and that there is disagreement in the reliability of markers 
used in flow cytometry [144]. 
 
5.3  Limitations and methodological optimization 
 
One of the main limitations in this project was the availability of patient material, as APS-1 is 
a very rare disease. The low sample volume and variable number of cells, in addition to the 
small patient and control groups makes the results less reliable. To improve this, the frequency 
of sample collection or the amount of PBMC could have been increased. Also avoiding the 
freezing step could have improved the number of PBMC in the samples, as this step may induce 
cell death. But due to the limited time frame and the need to avoid frequent blood sampling of 
patients, this was not achievable. Other factors such as genetic background of both the patients 
and controls may also affect the results, and in this case the controls´ backgrounds were not 
known. Further, it is likely that the patients are treated with medications that might have 
influence on the results, but it was not possible to adjust for these factors. Finally, the presence 
of other cells than T cells in PBMC may affect these observations, as PBMC includes B cells, 
monocytes, NK cells in addition to T cells [145].  
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When comparing the methods used in this project with others who identified an expanded Treg 
population in cell culture there were some differences. Other studies used isolated CD4+ T cells 
or Treg in cell culture [131, 143]. We used PBMC to study the effect of rapamycin due to the 
small number of cells, where an isolation of CD4+ cells or Treg would have decreased it even 
more. The concentration of rapamycin was also different in some studies, where some claimed 
that a low dose (1 nM-10 nM) of rapamycin did not expand the population of Treg, but a 
concentration of at least 100 nM was needed [143]. On the other hand, some suggests that a 
concentration of 1 nM did induce an expansion of this population, but that 100 nM gave an 
even larger expansion [141]. These studies were performed on isolated Treg in cell culture for 
1-6 weeks, in some of the experiments the cells were re-stimulated several times in cell culture, 
with anti-CD3 and –CD28 and IL-2 [141, 142]. In our protocol the cells were only stimulated 
with anti-CD3 and-CD28 once together with the concentration of 4 nM rapamycin. 
Modification of the protocol could include a longer time in cell culture and a broader titration 
line with concentrations up to 100 nM. However, we were also afraid to go too high in 
concentration and induce unnecessary cell deaths. Another factor is the half-life of rapamycin, 
which in human it is about 57-63 hours [112], however this is not transferable to cell culture, 
in an in vitro environment. Still, it would be interesting to assess the effect after a second 
treatment during the time in culture.   
 
The protocol used for flow cytometry was well established in the lab prior to this project, which 
was timesaving. However, additional markers for anergy and autophagy could have been useful 
to assess the effect of rapamycin. Studies have different opinions if rapamycin induces anergy 
or not. A study of alloreactive human T cells suggested that rapamycin do not induce anergy 
but inhibited the proliferative capacity, another study of autoreactive T cells suggested that 
rapamycin induced anergy due to blocking the cell cycle progression [146, 147].  A study of 
anergic cells in mice suggested that the  cell surface markers PD-1, CD7, CD28 and CD4 could 
be used to identify anergic cells [148]. To detect the presence of autophagy, anti-LC3-II was 
used in a study looking at the rapamycin induced autophagy [149]. As rapamycin is suggested 
to induce T cell cycle arrest in G1 phase to S, a marker for this would also be helpful to assess 
the effect of rapamycin [103]. It is further possible that the choice of markers or gating strategy 
used did not manage to gate for a pure Treg population, as Treg represent a small cell population. 
A possible way to make it easier to assess the effect of rapamycin on Treg could be to isolate 
this T cells population, or add additional markers, such as CD127, a marker suggested to be 
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expressed in a low frequency on Treg [143]. However, Treg isolation was not performed in this 
project due to the limited time frame, and limited numbers of available cells.  
 
In the study of gene expression in activated cells, it could have been useful to look at the 
expression of PTEN, as high levels of PTEN have been observed in Treg. PTEN is suggested to 
block the downstream event in the PI3K pathway in Treg, thereby not being sensitive to 
rapamycin [141]. It could also be interesting to look at the expression of S6K1 in the cells after 
treatment with rapamycin, as this gene is regulated by mTORC1 [91].  
6. Concluding remarks 
 
In this study, we aimed to investigate the effect of rapamycin on cells from APS-1 patients and 
to establish a cell-based system to assess the effect of drugs. We introduced rapamycin as a 
potential treatment of APS-1 and found only minor differences between the controls and 
patients. The only significant differences were the decrease of CD39 in the patients and 
decrease of CD31 in the controls. However, the immunosuppressive effect of rapamycin was 
similar in APS-1 patients and controls evidenced by the decreased cell proliferation for 
both groups. 
 
With a limited number of APS-1 patients, the power of this study is not high enough do make 
any general conclusions. However, we here established an in vitro cell culture system to analyse 
the effect of rapamycin, which can also be used for screening of other potential drugs on patient 
cells in the future. 
7. Future perspectives 
 
We successfully established a cell-based system to treat PBMC in vitro with rapamycin. To 
further assess the effect of the drug, the use of phosphospecific flow cytometry would have 
been useful. This method allows for  measuring the intracellular signaling pathway to follow 
the activation of the cell at a single-cell level [150, 151]. Also assessing the levels of IL-10 and 
TGF-b would have been helpful tools to identify a possible Treg expansion, as other studies has 
identified an increased level of these cytokines after treatment with rapamycin [152]. It would 
further be interesting to assess the effect of other rapalogues and drugs expanding the Treg 
population, such as Rabbit anti-thymocyte globulin (rATG) [153]. Humanized mouse models 
could be beneficial tools in pre-clinical testing of drugs and to further study the disease, in order 
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to get access to more relevant cells and tissue that are not available from patients, due to ethical 
reasons [154, 155]. As the symptoms in APS-1 patients has a variable onset, there is a need of 
early identification of the symptoms to slow it down. This brings challenges with the need to 
avoid frequent blood sampling and diagnostic procedures, to avoid putting individuals at risk. 
 
Patients with APS-1 suffer from a rare disease with limited treatment options and the best target 
of treatment is yet to be identified. The use of Treg therapy in autoimmune diseases is constantly 
being brought up to date as it has shown to provide a better treatment for other severe 
autoimmune conditions, such as IPEX and SLE [108, 109]. Treg therapy may be a good option 
at the moment as the knowledge of this T cell population is rapidly expanding in the area of 
autoimmune diseases [156]. Novel approaches are needed for further progress in this area of 
medicine, with a need of targeted and personalized medicine, as there is a broad variation in 
symptoms. To achieve this there is a great need of specialized methods to understand the 
complexity of the diseases, where single cell technology has shown to improve the knowledge 
in diagnostic procedures in the field of autoimmunity [157, 158]. By using such methods, 
including polychromatic flow cytometry and gene sequencing techniques, the knowledge of 
endocrine immune diseases has improved, and even more advanced methods has made it 
possible to dig deeper into the complexity and perhaps identify therapeutic targets [159]. 
However, there are still a need for further identification of therapeutic targets in APS-1 and 
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Table A.2 List of included controls 
No. Sex Year of birth 
1 Male 1990 
2 Male 1960 
3 Female 1971 
4 Female 1979 
5 Male 1971 
6 Male 1986±5 years  
7 Male 1955±5 years 
8 Male 1948±5 years 
9 Male 1970±5 years 
10 Femal 1957±5 years 
11 Male 1980±5 years 
12 Female 1990±5 years 
13 Male 1986±5 years 





Table A.3: Number of live cells before and after isolation. 
Samples Number of live cells before isolation 
(•106) 
Number of live cells after isolation 
(•106) 
Controls 
Control 1 4.29 3.80 
Control 2 6.50 1.97 
Control 3 4.66 3.33 
Control 4 1.93 1.20 
Control 5 3.04 2.70 
Patients 
Patient 1 6.70 5.89 
Patient 2 2.92 1.87 
Patient 3 7.19 1.50 
Patient 4 5.60 3.47 
Patient 5 7.3 6.84 
 
 
Table A.4: List of genes in the mTOR signaling pathway included in the qPCR with resting cells  
 






AKT1 V-akt murine thymoma viral oncogene homolog 1 0,70 
AKT1S1 AKT1 substrate 1 (proline-rich) 0,72 
AKT2 V-akt murine thymoma viral oncogene homolog 2 0,84 
AKT3 V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, 
gamma) 
0,83 
CAB39 Calcium binding protein 39 0,76 
CAB39L Calcium binding protein 39-like 0,98 
CDC42 Cell division cycle 42 (GTP binding protein, 25kDa) 0,71 
CHUK Conserved helix-loop-helix ubiquitous kinase 0,82 
DDIT4 DNA-damage-inducible transcript 4 -* 
DDIT4L DNA-damage-inducible transcript 4-like 0,78 
DEPTOR DEP domain containing MTOR-interacting protein 0,75 
EIF4B Eukaryotic translation initiation factor 4B 1,27 
EIF4E Eukaryotic translation initiation factor 4E 0,86 
EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1 0,83 
EIF4EBP2 Eukaryotic translation initiation factor 4E binding protein 2 0,81 
FKBP1A FK506 binding protein 1A, 12kDa 0,82 
FKBP8 FK506 binding protein 8, 38kDa 0,90 
GSK3B Glycogen synthase kinase 3 beta 0,88 
HIF1A Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) 
0,96 
HRAS V-Ha-ras Harvey rat sarcoma viral oncogene homolog 1,10 
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HSPA4 Heat shock 70kDa protein 4 0,62 
IGF1 Insulin-like growth factor 1 (somatomedin C) 0,91 
IGFBP3 Insulin-like growth factor binding protein 3 0,76 
IKBKB Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase 
beta 
0,96 
ILK Integrin-linked kinase 3,41 
INS Insulin 0,73 
INSR Insulin receptor 0,99 
IRS1 Insulin receptor substrate 1 0,86 
MAPK1 Mitogen-activated protein kinase 1 0,94 
MAPK3 Mitogen-activated protein kinase 3 1,04 
MAPKAP1 Mitogen-activated protein kinase associated protein 1 0,93 
MLST8 MTOR associated protein, LST8 homolog (S. cerevisiae) 1,22 
MTOR Mechanistic target of rapamycin (serine/threonine kinase) 0,94 
MYO1C Myosin IC 1,43 
PDPK1 3-phosphoinositide dependent protein kinase-1 0,94 
PIK3C3 Phosphoinositide-3-kinase, class 3 1,06 
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide 1,00 
PIK3CB Phosphoinositide-3-kinase, catalytic, beta polypeptide 1,00 
PIK3CD Phosphoinositide-3-kinase, catalytic, delta polypeptide 0,85 
PIK3CG Phosphoinositide-3-kinase, catalytic, gamma polypeptide 0,72 
PLD1 Phospholipase D1, phosphatidylcholine-specific 0,91 
PLD2 Phospholipase D2 0,94 
PPP2CA Protein phosphatase 2, catalytic subunit, alpha isozyme 0,82 
PPP2R2B Protein phosphatase 2, regulatory subunit B, beta 0,82 
PPP2R4 Protein phosphatase 2A activator, regulatory subunit 4 1,02 
PRKAA1 Protein kinase, AMP-activated, alpha 1 catalytic subunit 0,95 
PRKAA2 Protein kinase, AMP-activated, alpha 2 catalytic subunit 0,86 
PRKAB1 Protein kinase, AMP-activated, beta 1 non-catalytic subunit 0,93 
PRKAB2 Protein kinase, AMP-activated, beta 2 non-catalytic subunit 0,83 
PRKAG1 Protein kinase, AMP-activated, gamma 1 non-catalytic subunit 0,86 
PRKAG2 Protein kinase, AMP-activated, gamma 2 non-catalytic subunit 1,47 
PRKAG3 Protein kinase, AMP-activated, gamma 3 non-catalytic subunit 0,99 
PRKCA Protein kinase C, alpha 1,89 
PRKCB Protein kinase C, beta 0,90 
PRKCE Protein kinase C, epsilon 0,90 
PRKCG Protein kinase C, gamma 0,94 
PTEN Phosphatase and tensin homolog 1,05 
RHEB Ras homolog enriched in brain 1,27 
RHOA Ras homolog gene family, member A 1,07 
RICTOR RPTOR independent companion of MTOR, complex 2 1,05 
RPS6 Ribosomal protein S6 1,03 
RPS6KA1 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 1,52 
RPS6KA2 Ribosomal protein S6 kinase, 90kDa, polypeptide 2 0,85 
RPS6KA5 Ribosomal protein S6 kinase, 90kDa, polypeptide 5 0,80 
RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1 0,91 
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RPS6KB2 Ribosomal protein S6 kinase, 70kDa, polypeptide 2 1,35 
RPTOR Regulatory associated protein of MTOR, complex 1 1,44 
RRAGA Ras-related GTP binding A 0,84 
RRAGB Ras-related GTP binding B 0,66 
RRAGC Ras-related GTP binding C 1,10 
RRAGD Ras-related GTP binding D 1,12 
SGK1 Serum/glucocorticoid regulated kinase 1 0,69 
STK11 Serine/threonine kinase 11 0,80 
STRADB STE20-related kinase adaptor beta 1,42 
TELO2 TEL2, telomere maintenance 2, homolog (S. cerevisiae) 0,96 
TP53 Tumor protein p53 1,09 
TSC1 Tuberous sclerosis 1 1,37 
TSC2 Tuberous sclerosis 2 1,43 
ULK1 Unc-51-like kinase 1 (C. elegans) 1,08 
ULK2 Unc-51-like kinase 2 (C. elegans) 1,03 
VEGFA Vascular endothelial growth factor A 1,09 
VEGFB Vascular endothelial growth factor B 1,21 
VEGFC Vascular endothelial growth factor C 1,35 
YWHAQ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, theta polypeptide 
1,17 
ACTB Actin, beta 1,22 
B2M Beta-2-microglobulin 0,69 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0,80 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 1,27 
RPLP0 Ribosomal protein, large, P0 0,70 
HGDC Human Genomic DNA Contamination 0,72 
*The samples were undetectable. 
 
Table A.5: Titration lines used to determine rapamycin concentration 
Concentration (nM) Frequency of live cells (%) Proliferation index 
Titration line one (control 14) 
0 34,8 2,19 
0,05 36,7 1,06 
0,1 35,5 1,22 
1 47,4 1,56 
2 30,7 1,93 
Titration line two (control 1) 
0 83,0 2,09 
2 78,2 1,65 
4 78,5 1,56 
Titration line two (patient 1) 
0 76,4 2,27 
2 78,5 1,56 




Table A.6: Comparison of live cells with the respective markers for untreated and treated samples in 
patients and controls. 
 
Markers Median difference between 
untreated (-) and treated (+) 
cells, controls (95% CI) 
Median difference between 
untreated (-) and treated (+) 




















































A.7: Comparison of live cells with the respective markers in Treg for untreated and treated samples in 




Median difference between 
untreated (-) and treated (+) 
cells, controls (95% CI) 
Median difference between 
untreated (-) and treated (+) 



























*Non-parametric Mann-Whitney test, results were found significant if P < 0.05. 
 
 
